610 Medizin und Gesundheit
Refine
Year of publication
- 2013 (350) (remove)
Document Type
- Article (265)
- Doctoral Thesis (34)
- Conference Proceeding (14)
- Part of Periodical (14)
- Contribution to a Periodical (12)
- Book (3)
- Review (3)
- Part of a Book (2)
- Periodical (2)
- Preprint (1)
Is part of the Bibliography
- no (350)
Keywords
- Video (19)
- Capsule endoscopy (12)
- Small bowel (10)
- Endoscopy (7)
- Balloon enteroscopy (6)
- Enteroscopy (6)
- Endoscopic retrograde cholangiopancreatography (4)
- Apoptosis (3)
- IAP proteins (3)
- Smac (3)
- epigenetics (3)
- Atrial fibrillation (2)
- Begriff (2)
- Begriffsgeschichte <Fach> (2)
- Bile duct stone (2)
- Blog (2)
- Breast cancer (2)
- CBA (2)
- COPD (2)
- Cholangiography (2)
- Cholangiopancreatography (2)
- Colonoscopy (2)
- Colorectal cancer (2)
- Double-balloon enteroscopy (2)
- Endoscopic retrograde (2)
- Enterscopy (2)
- Extended donor criteria (2)
- Gesichtsauflösung (2)
- Hemorrhage (2)
- Herb induced liver injury (2)
- IL-6 (2)
- KGF (2)
- Lymphectasia (2)
- Migration (2)
- PDGFRβ (2)
- ROS (2)
- Rhabdomyosarcoma (2)
- SD-OCT (2)
- Sestrin 2 (2)
- Social Media (2)
- Standard endoscopy (2)
- Stroke (2)
- Thrombolysis (2)
- VEGF (2)
- Web 2.0 (2)
- apoptosis (2)
- cardiac (2)
- cell death (2)
- gamma (2)
- glioblastoma (2)
- immunotherapy (2)
- leukemia (2)
- radiotherapy (2)
- schizophrenia (2)
- signal transduction (2)
- synchrony (2)
- therapy (2)
- ALL (1)
- AML (1)
- Actin (1)
- Adenocarcinoma (1)
- Adhesion (1)
- Adolescence (1)
- Airways (1)
- Allergy (1)
- Angiectasia (1)
- Angiodysplasia (1)
- Antibiotic generic drugs (1)
- Anticoagulation (1)
- Antifungal agents (1)
- Antineoplastic agents (1)
- Antiretrovirals (1)
- Antiviral therapy (1)
- Aortic debranching (1)
- Aortic dissection (1)
- Aromatase inhibitors (1)
- Arteriovenous malformation (1)
- Aspergillosis (1)
- Assessment (1)
- Asthma (1)
- Augenheilkunde (1)
- Augenverletzungen (1)
- Auric nanoparticles (1)
- Autism spectrum disorder (1)
- B-cell (1)
- B16 cells (1)
- BCL2 (1)
- BCR-ABL (1)
- BRVO (1)
- Ballet (1)
- Ballon-assisted enteroscopy (1)
- Bcl-2 (1)
- Befindlichkeit (1)
- Benign disorder (1)
- Bevacizumab (1)
- Bewältigung (1)
- Bildnis (1)
- Billroth II gastroenterostomy (1)
- Billroth papillotome (1)
- Billroth’s operation-II (1)
- Blood-brain barrier (1)
- Bortezomib (1)
- Brain (1)
- Brain development (1)
- Brain repair (1)
- Burnout-Syndrom (1)
- C1-inhibitor deficiency (1)
- CIOMS (1)
- CRVO (1)
- CXCL12 (1)
- CXCR4 (1)
- Cancer (1)
- Cancer stem cells (1)
- Candida (1)
- Capecitabine (1)
- Capsule endoscopy, video (1)
- Cardiac surgery (1)
- Castleman’s disease (1)
- Catheter ablation (1)
- Celiac disease (1)
- Cell Death (1)
- Cell Signaling (1)
- Cell Surface Receptor (1)
- Cellular Immune Response (1)
- Cerasorb (1)
- Cerebral Vasospasm (1)
- Chemoradiotherapy (1)
- Chronic illness (1)
- Chronic obstructive airway disease (1)
- Clip (1)
- Cohort study (1)
- Communication (1)
- Comparative study (1)
- Coordination Of Control Modes (1)
- Core needle biopsy (1)
- Coronary artery disease (CAD) (1)
- Cost And Quality Management (1)
- Crohn’s disease (1)
- Cryoablation (1)
- Cyanoacrylate (1)
- Cytochrome P450 (1)
- Cytokine (1)
- Cytotoxicity (1)
- DNA Adducts (1)
- DR5 (1)
- Dancer (1)
- Delayed Cerebral Ischemia (1)
- Dentin adhesives (1)
- Dermatologie (1)
- Device (1)
- Diabetic nephropathy (1)
- Dieulafoy’s lesion (1)
- Digestive system (1)
- Dilated cardiomyopathy (1)
- Disease management (1)
- Docetaxel (1)
- Doctors In Management (1)
- Double balloon enteroscopy (1)
- Doubling time (1)
- Drug Therapy (1)
- Drug hepatotoxicity (1)
- Drug induced liver injury (1)
- Duodenum (1)
- EEG (1)
- EWS/Fli1 (1)
- Ectopic bone formation (1)
- Ectopic varices (1)
- Effectivity (1)
- Elderly (1)
- Ellipticine (1)
- Endomicroscopy (1)
- Endoscopic papillotomy (1)
- Endoscopic retrograde cholangiography (1)
- Endoscopic sphincterotomy (1)
- Endoscopic treatment (1)
- Endoscopic ultrasound (1)
- Energieumsatz <Medizin> (1)
- Entzündung (1)
- Erschöpfung (1)
- Esophagogastric (1)
- Europe (1)
- European Comparison (1)
- Ewing sarcoma (1)
- Exemestane (1)
- FAP (1)
- FTY720 (1)
- Facet joint osteoarthritis (1)
- Fast-track (1)
- Female (1)
- Fever (1)
- Fibrinolytic (1)
- Fingolimod (1)
- G-CSF (1)
- Gastric adenoma (1)
- Gastric cancer (1)
- Gastritis (1)
- Gastrointestinal bleeding (1)
- Gene polymorphism (1)
- Generic drugs (1)
- Gesicht (1)
- Gesicht <Motiv> (1)
- Gewebedurchblutung (1)
- Gewebetemperatur (1)
- Giant lymph node hyperplasia (1)
- Glivec® (1)
- Glomerulonephritis (1)
- Gold (1)
- Graft function (1)
- Graft survival (1)
- Graz <2013> (1)
- HAE (1)
- HDACi (1)
- HIV therapy (1)
- HNPCC (1)
- HSPC (1)
- Heart (1)
- Hebbian plasticity (1)
- Hematologic malignancies (1)
- Hemobilia (1)
- Hepatitis C (1)
- Herbalife products (1)
- Hexavalent vaccine (1)
- Hormonal (1)
- Hospital Governance (1)
- Hydroxyapatite (1)
- ICU (1)
- IMiD® (1)
- ISO (1)
- Identity (1)
- Identität (1)
- Immunology (1)
- In-vivo (1)
- Infektionsabwehr (1)
- Infektionskrankheit (1)
- Inflammatory bowel disease (1)
- Inflammatory fibroid polyp (1)
- Infrarot (1)
- Innate Immunity (1)
- Innate immunity (1)
- Integrin (1)
- Intestinal fistula (1)
- Intestinal metaplasia (1)
- Intestinal neoplasms (1)
- Invasive candidiasis (1)
- Ischemia (1)
- Ischemia-reperfusion injury (1)
- Kava (1)
- Kidney disease (1)
- Kinderwunsch (1)
- Kommunikation (1)
- Kongress (1)
- Krankheit (1)
- Krankheitsbegriff (1)
- Künste (1)
- Landmark (1)
- Langerhans cell histiocytosis (1)
- Lebensbewältigung (1)
- Lebensgefühl (1)
- Liver biopsy (1)
- Liver histology (1)
- Liver injury (1)
- Liver transplantation (1)
- Lumbar stenosis (1)
- Lung (1)
- Lymphangiectasia (1)
- Lymphoepithelioma (1)
- Lymphoma (1)
- MACE (1)
- MCAO (1)
- MCP (1)
- MCP-1 (1)
- MEG (1)
- MLL (1)
- MTCL (1)
- MTT (1)
- Male (1)
- Marginal grafts (1)
- Medizin (1)
- Medizinische Ausbildung (1)
- Mena/VASP (1)
- Metal clip (1)
- Metapher (1)
- Metastatic (1)
- Mid-intestinal bleeding (1)
- Minimally invasive transforaminal interbody fusion (1)
- Missbildung (1)
- Moderating factors (1)
- Multiple trauma (1)
- Mund-Kiefer-Gesichts-Chirurgie (1)
- Mycoses (1)
- NF-κB (1)
- NK Receptor (1)
- NK cell (1)
- NS3-4A protease inhibitor (1)
- NS5B polymerase inhibitor (1)
- NanoBone (1)
- Nanocrystalline (1)
- Natural Killer (NK) Cell (1)
- Neoadjuvant radiochemotherapy (1)
- Neoadjuvant treatment (1)
- Nerven <Begriff> (1)
- Neural function (1)
- Neural stem cells (1)
- Neurasthenie (1)
- Neuroendocrine tumor (1)
- Neurogenesis (1)
- Neurotransmitter (1)
- New Developments (1)
- Nicht-Ereignis (1)
- Non-Hodgkin lymphoma (1)
- Occupational disease (1)
- Occupational exposure (1)
- Occupational health (1)
- Oesophagogastric cancer oxaliplatin (1)
- Off-pump surgery (1)
- Oncolytic virus (1)
- Oncotargets (1)
- Online-Magazin (1)
- Online-Magazine (1)
- Organ allocation (1)
- Organ rinse (1)
- Organ shortage (1)
- Osteoinduction (1)
- Osteoporosis (1)
- Outcome (1)
- Over-the-scope clip (1)
- Oxaliplatin (1)
- PAX3/FOXO1 (1)
- PET (1)
- Pancreas transplantation (1)
- Paracetamol (1)
- Paraneoplastic syndrome (1)
- Pathologic complete response (1)
- Pelargonium sidoides (1)
- Percutaneous ultrasound (1)
- Peroxidase (1)
- Personality disorder (1)
- Peutz–Jeghers syndrome (1)
- Pharmacodynamic (1)
- Philosophie (1)
- Physical therapist (1)
- Planning target volume (1)
- Platelets (1)
- Pneumococcal conjugate vaccine (1)
- Polyposis syndrome (1)
- Postoperative anatomy (1)
- Preoperative radiochemotherapy (1)
- Professionalism (1)
- Prophylaxis (1)
- Protein Expression (1)
- Psychopathology (1)
- Pulmonary failure (1)
- Pulmonary veins (1)
- Qualitative research (1)
- RAD001 (1)
- RIP1 (1)
- RNA interference (RNAi) (1)
- RUNX1/ETO (1)
- Radiation induced diarrhoea (1)
- Radiotherapy (1)
- Rare disease (1)
- Readmission (1)
- Rectal cancer (1)
- Rejection (1)
- Religiöses Coping (1)
- Restenosis (1)
- S1P1 receptor (1)
- SERS (1)
- SOCS (1)
- Sauerstoffpartialdruck im Gewebe (1)
- Sauerstoffversorgung (1)
- Schmerz (1)
- Schmerzminderung (1)
- Sekretion (1)
- Selenium administration in gynecologic radiation oncology (1)
- Self-expandable metal stents (1)
- Self-expandable metal stents complications (1)
- Self-management support (1)
- Signaling (1)
- Small-bowel endoscopy (1)
- Social skills training (1)
- Spectrin (1)
- Sphingolipid (1)
- Sphingosine 1-phosphate (1)
- Spondylolisthesis (1)
- Sportmedizin (1)
- Sportophthalmologie (1)
- Sportärztekongress (1)
- Stentoplasty (1)
- Study protocol (1)
- Subacute cerebellar degeneration (1)
- Subarachnoid Hemorrhage (1)
- Subfertilität (1)
- Supraventricular arrhythmias (1)
- Syk Kinase (1)
- T cell (1)
- T-cell homeostasis (1)
- T-cell niche (1)
- TEM (1)
- TEVAR (1)
- TKI (1)
- TRAIL (1)
- Tacrolimus (1)
- Tamoxifen (1)
- Temozolomide (1)
- Terminal ileitis (1)
- Thalidomide (1)
- Thoracic trauma (1)
- Thyroid Cancer Cells (1)
- Toll-like receptor (TLR) 6 (1)
- Tonsil (1)
- Toxicology (1)
- Toxins (1)
- Traumatic injury (1)
- Treatment (1)
- Tumor (1)
- Tumor obstruction (1)
- Tumor subtype (1)
- Ultrasonography (1)
- Unfallverletzung (1)
- Ungewollte Kinderlosigkeit (1)
- VEGF receptors (1)
- VIP (1)
- VPAC1 (1)
- Variceal bleeding (1)
- Vertebral augmentation (1)
- Vertebral body stenting (1)
- Vertebral fracture (1)
- Virotherapy (1)
- Vitreous samples (1)
- Western Blotting (1)
- Wilms tumor (1)
- Wissenschaft (1)
- Wunde (1)
- Wundheilung (1)
- Wundinfektion (1)
- YB-1 (1)
- Zivilisationskrankheit (1)
- active perception (1)
- acute leukemia (1)
- acute lymphoblastic leukaemia (1)
- acute myeloid leukaemia (1)
- ageing (1)
- aging (1)
- air pouch (1)
- all-ceramic (1)
- allogeneic hematopoietic stem cell transplantation (1)
- alpha peak (1)
- antifungal agents (1)
- antifungal management (1)
- antifungal prophylaxis (1)
- astrocyte (1)
- astrocytes (1)
- atherosclerosis (1)
- attention (1)
- barriers to implementation (1)
- biocompatibility (1)
- bone morphogenetic protein-2 (1)
- bone substitute material (1)
- bortezomib (1)
- brain injury (1)
- cancer (1)
- cardiovascular (1)
- cardiovascular disease (1)
- chemotherapy (1)
- childhood cancer (1)
- chromosomal translocations (1)
- chronic care (1)
- cigarette (1)
- clinical research (1)
- clinical study (1)
- clinical trials (1)
- cochlear implant (1)
- cognition (1)
- consciousness (1)
- corticomuscular coherence (CMC) (1)
- costs (1)
- crestal bone loss (1)
- critical periods (1)
- crowns (1)
- deconvolution (1)
- development (1)
- directly acting antiviral agents (1)
- distraction (1)
- dual task (1)
- endothelial (1)
- entorhinal cortex lesion (1)
- everolimus (1)
- exercise (1)
- expert review (1)
- fMRI (1)
- finger tapping (1)
- functional MRI (1)
- fungal infection (1)
- gastric (1)
- gastrointestinal (1)
- gene therapy (1)
- glutamate metabolism (1)
- granulocyte (1)
- growth factor (1)
- hand area (1)
- head and neck cancer (1)
- hematopoietic stem and progenitor cells (1)
- hemodialysis (1)
- hepatitis C virus (1)
- hereditary angioedema (1)
- hippocampal volume (1)
- homeostatic synaptic scaling (1)
- iPS (1)
- immune function (1)
- immunocytochemistry (1)
- immunology (1)
- implant (1)
- implant survival (1)
- inflammation (1)
- inhibition of DNA-binding (1)
- interferon-free (1)
- interleukin-10 (1)
- interleukin-22 (1)
- invasive fungal infection (1)
- kidney disease (1)
- lenalidomide (1)
- long-term survival (1)
- mTOR (1)
- magnetoencephalography (1)
- magnetoencephalography (MEG) (1)
- marginal bone loss (1)
- mature T-cell lymphoma (1)
- memory (1)
- metaplasticity (1)
- miRNA (1)
- miRNA-17–92 (1)
- microRNA (1)
- mild cognitive impairment (1)
- mitogen-activated protein kinase (1)
- mitomycin C (1)
- mobilization (1)
- monogenic disorders (1)
- motor control (1)
- motor task (1)
- nanoparticles (1)
- natural killer cell (1)
- necroptosis (1)
- neurobiology (1)
- neuroblastoma (1)
- neurodegeneration (1)
- neurological diseases (1)
- neurooncology (1)
- neuropsychiatric disorders (1)
- next-generation sequencing (1)
- non-invasive brain stimulation (1)
- oligodendrocyte (1)
- organotypic slice cultures (1)
- oscillations (1)
- oxidative stress (1)
- pain (1)
- peptide aptamer (PA) (1)
- perceptual organization (1)
- plasticity (1)
- posaconazole (1)
- pregnancy (1)
- pregnant (1)
- preprocedure prophylaxis (1)
- prevention (1)
- primary motor cortex (1)
- primary motor cortex (M1) (1)
- prognostic value (1)
- progranulin (1)
- prostate and breast cancer cell lines (1)
- prostate cancer (1)
- proteasome inhibitor (1)
- protein transduction (1)
- rat femur defect (1)
- receptor tyrosine kinase (1)
- reduction of pain (1)
- reinforcement learning (1)
- resting state (1)
- robotics (1)
- robustness (1)
- scaffolding proteins (1)
- sciatic nerve injury (1)
- self-management support (1)
- senescence (1)
- signal transducer and activator of transcription (1)
- signal transducer and activator of transcription 5 (Stat5) (1)
- signaling (1)
- single-sided deafness (1)
- sleep (1)
- slowing (1)
- smoking (1)
- sonic hedgehog (1)
- sparse coding (1)
- stem cell therapy (1)
- stem/progenitor cell expansion (1)
- stereo vision (1)
- structural plasticity (1)
- surgical procedures (1)
- survival rate (1)
- thalidomide (1)
- therapeutics (1)
- three point bending test (1)
- tissue blood flow (1)
- tissue oxygen partial pressure (1)
- tissue temperature (1)
- tobacco (1)
- tooth wear (1)
- toxicity (1)
- transcranial alternating current stimulation (tACS) (1)
- translocation partner genes (1)
- tricalcium phosphate (1)
- tumour-infiltrating lymphocytes (1)
- type I interferons (1)
- vascular (1)
- vergence (1)
- viral vectors (1)
- vitreous samples (1)
- wIRA (1)
- wassergefiltertes Infrarot A (1)
- water-filtered infrared-A (wIRA) (1)
- yeast-two-hybrid (Y2H) (1)
- Ätiologie (1)
- ß-tricalciumphosphate (1)
Institute
Glioblastoma is the most common and most aggressive type of brain tumor in adults. In contrast to epithelial cancers, glioblastomas do not metastasize. While the major treatment challenge in epithelial cancers is not the primary tumor but metastasis, glioblastoma patients die of the primary tumor.
However, there is a common theme which underlies the malignant properties of progressed epithelial cancers and glioblastoma: invasion from the primary tumor into the surrounding tissue. In the case of epithelial cancers this is the first and necessary step to metastasis, whereas invasion leads inevitably to tumor recurrence after resection in the case of glioblastoma, causing it to be incurable.
A cellular program which has been described in detail to promote the invasive phenotype in epithelial tumors, is the epithelial-mesenchymal-transition (EMT). Differentiated neural cells are not epithelial, thus, strictly speaking, EMT does not occur in glioblastoma. However, the traits acquired in the process of EMT, especially invasiveness and stemness, are highly relevant to glioblastoma. One of the key transcription factors known to induce EMT in epithelial cancers is ZEB1, which has been described only marginally in the central nervous system so far. Here, I investigate the expression and function of ZEB1 in glioblastoma and during human fetal neural development.
ZEB1 mRNA was significantly upregulated in all histological types of glioma, including glioblastoma, when compared to normal brain. There was no correlation between ZEB1 mRNA levels and tumor grade. Immunohistochemical staining of glioma samples demonstrated that ZEB1 was highly expressed in the great majority of tumor cells. In the developing human brain, intense staining for ZEB1 could be observed in the ventricular and subventricular zone, where stem- and progenitor cells reside. ZEB1 positive cells included cells stained with stem- and progenitor markers like PAX6, GFAP and Nestin. In contrast, ZEB1 was never found in early neuronal cells as identified by TUBB3 staining.
To gain insight into ZEB1 function I generated a human fetal neural stem cell line and a glioblastoma cell line with ZEB1 knockdown, which were compared with their respective control cell lines. First, I found that ZEB1 does not regulate the micro RNA 200 family in either cell line, which has been described as an essential ZEB1 target in epithelial cancers. Second, regulated target genes were identified with a genome wide microarray. The third approach was to directly identify genomic binding sites of ZEB1 by chromatin immunoprecipitation sequencing (ChIP-seq). All three approaches showed that the ZEB1 transcriptional program is surprisingly similar in the neural stem cell line and the glioblastoma cell line. In contrast, it bears only little resemblance to the program described in epithelial cancers.
The most interesting, previously unrecognized ZEB1 target gene identified in this study is integrin b1. It was regulated after ZEB1 knockdown detected by microarray analysis, and has a ZEB1 binding site in its promoter region detected by ChIP-seq. Finally, I addressed the question whether ZEB1 influences tumor growth and invasiveness in a glioblastoma model. After intracranial xenotransplantation in mice, ZEB1 knockdown glioblastoma cells formed significantly smaller and less invasive tumors than control glioblastoma cells.
This study demonstrates that ZEB1 is widely expressed in glioma and relevant for glioblastoma growth and invasion. In contrast to what is known about ZEB1 function in epithelial cancers, ZEB1 is not associated with glioma progression, but instead seems to be an early and necessary event in tumorigenesis. Also with regard to ZEB1 target genes, ZEB1 functions differently in glioblastoma than in epithelial cancers. The two most important ZEB1 targets in epithelial cancers are E-cadherin and the miR-200 family members. Both are not relevant to ZEB1 function in glioblastoma. Interestingly, while the ZEB1 transcriptional program is different from the one described in epithelial cancers, it is highly similar in glioblastoma cells and fetal neural stem cells. This suggests that an embryonic pathway restricted to stem- and progenitor cells during development is reactivated in glioblastoma.
Previously known ZEB1 target genes were tissue specific and therefore seemed unlikely to mediate ZEB1 function in the central nervous system. However, the newly identified ZEB1 target gene integrin b1 is well known to play pivotal roles in both glioblastoma tumorigenesis and invasion as well as in neural stem cells. Additionally, integrin b1 is widely expressed and seems a likely ZEB1 target in other organs than the brain.
Taken together, I demonstrate that ZEB1 is a new regulator of glioblastoma growth and invasion. The transcriptional program of ZEB1 differs from the one in epithelial cancers but is strikingly similar to the one in neural stem cells. The newly identified ZEB1 target gene integrin b1 is likely to mediate crucial ZEB1 functios. Thus, this study identifies ZEB1 as a yet unrecognized player in glioblastoma and neural development. Furthermore, it sets the stage for more research which will help to deepen our understanding of ZEB1 function in the central nervous system and beyond.
C-Typ Lektin-ähnliche Rezeptoren (CTLRs) auf Lymphozyten des Immunsystems modulieren deren Effektorfunktionen wie Zytotoxizität oder Zytokinsekretion. Die Gene dieser Immunrezeptoren befinden sich in einer definierten genomischen Region, dem Natürlichen Killer Genkomplex (NKC), welcher im Menschen auf Chromosom 12 und in der Maus auf Chromosom 6 lokalisiert ist. Namensgebend für diesen Gencluster ist die erste Beschreibung von CTLRs auf Natürlichen Killerzellen (NK-Zellen), den Effektorlymphozyten des angeborenen Immunsystems. Einige NKC-kodierte CTLR, insbesondere Vertreter der C-Typ Lektin Familie 2 (CLEC2)-Rezeptorfamilie, werden jedoch auch in nicht-lymphozytären Zellen (z.B. humanes KACL in Keratinozyten, Maus Clr-f in Darmepithelzellen) vorgefunden und in Zusammenhang mit einer gewebsspezifischen Immunüberwachung gebracht. Bemerkenswerterweise sind die Lymphozytenassoziierten Rezeptoren dieser CLEC2-Proteine ebenso CTLRs, welche zudem eng benachbart zu den CLEC2-Proteinen im NKC kodiert sind, sodass es sich um genetisch gekoppelte Rezeptor-Liganden-Paare mit immunologischer Funktion handelt.
Zu Beginn der vorliegenden Arbeit richtete sich das Interesse auf ein bislang uncharakterisiertes Mitglied der CLEC2-Proteinfamilie (CLEC2L), das jedoch außerhalb des NKC und in unmittelbarer Nachbarschaft zu einem weiteren und ebenso uncharakterisierten CTLR (KLRG2) kodiert ist. Im Unterschied zu anderen Mitgliedern der CLEC2-Familie ist CLEC2L (wie auch KLRG2) in Säugetieren hochkonserviert. Im Rahmen dieser Arbeit wurde der Frage nachgegangen, ob CLEC2L wie andere Mitglieder der CLEC2-Proteinfamilie eine gewebsspezifische Expression aufweist, mit einem genetisch gekoppelten CTLR, d. h. mit KLRG2, interagiert und funktionell in Verbindung mit dem Immunsystem gebracht werden kann. Ziel dieser Arbeit war es somit, eine detaillierte Expressions- und Funktionsstudie zu CLEC2L durchzuführen.
Mittels quantitativer Echtzeit-PCR und in situ Hybridisierung konnte CLEC2L-RNA im humanen und Maus-Gehirn nachgewiesen werden. Da die Mengen dort das Expressionsniveau in anderen Organen bei Weitem überstiegen, wurde das CLEC2L-kodierte Protein als BACL (engl. Brain-Associated C-type Lectin) neu benannt. Ektop exprimiertes BACL bildet ähnlich wie viele andere CLEC2-Mitglieder ein disulfid-verknüpftes Homodimer auf der Zellmembran von Säugetierzellen. Um die endogene Proteinexpression dieses gehirnassoziierten „Waisen"-Rezeptors zu charakterisieren, wurde die BACL-Ektodomäne rekombinant produziert und als Immunogen zur Herstellung BACLspezifischer Antikörper eingesetzt. Mit diesen Antikörpern und einer Kombination immunologischer Techniken wie Immunhistochemie, Immunfluoreszenz und Immunpräzipitation konnte die Präsenz von BACL auf humanen und Maus-Neuronen des Gehirns mit einer besonders ausgeprägten Expression in Purkinje-Zellen zum ersten Mal gezeigt werden. Neben dem Gehirn wurden andere Bereiche des Nervensystems, darunter Spinalganglien und Retina, auf die Expression des BACL-Proteins untersucht. Hierbei konnte mittels Immunfluoreszenz und hochauflösender konfokaler Mikroskopie gezeigt werden, dass BACL mit Neuronenmembranen assoziiert ist. Die durchflusszytometrische Analyse von in vitro kultivierten Neurosphären untermauerte die Expression von endogenem BACL als membranständiges Oberflächenprotein.
Diverse Ansätze zur Identifizierung von Interaktionspartnern von BACL erbrachten letztlich keine eindeutigen Ergebnisse. KLRG2 wurde ursprünglich aufgrund seiner benachbarten genomischen Lokalisation als möglicher Rezeptor von BACL favorisiert, jedoch konnten weder Reporterassays noch durchflusszytometriebasierte Bindungsanalysen eine Interaktion dieser beiden Proteine aufzeigen. Auch die aus den massenspektrometrischen Analysen von humanen und Maus BACL-Immunpräzipitaten erhaltenen Kandidatenproteine konnten letztendlich nicht als Interaktionspartner von BACL eindeutig verifiziert werden.
Eine mögliche immunologische Bedeutung von BACL in vivo wurde im Rahmen von Tumorimplantationsexperimenten mit BACL-exprimierenden Tumorzellen untersucht. Hierbei wurde das Tumorwachstum von BACL- mit Kontroll-Transfektanten in C57BL/6 Mäusen verglichen. Der beobachtete Effekt des verlangsamten Tumorwachstums nach BACL-Überexpression war jedoch nicht auf BACL-Erkennung durch Lymphozyten zurückzuführen, wie anhand von immundefizienten Rag1-k.o. und NOD-SCID-gammak.o. Mäusen gezeigt werden konnte.
Insgesamt liefert diese Arbeit die Erstbeschreibung des bislang uncharakterisierten CTLRs BACL. Das Protein teilt strukturelle Merkmale mit Mitgliedern der CLEC2-Familie, unterscheidet sich jedoch deutlich durch (i) seine hohe Konservierung in Säugetieren, (ii) seine Kodierung außerhalb des NKC und (iii) seine pan-neuronale Expression. Die Erkenntnis, dass BACL in Maus- und in humanen Neuronen exprimiert wird, wirft die Frage nach seiner funktionellen Relevanz auf. Als Membranprotein könnte es eine wichtige Rolle in der neuronalen Kommunikation und bei zellulären Kontakten spielen. Die Frage nach der Funktion von BACL wird in zukünftigen Forschungsarbeiten zu klären sein.
Despite advances in allogeneic stem cell transplantation, BCR-ABL-positive acute lymphoblastic leukaemia (ALL) remains a high-risk disease, necessitating the development of novel treatment strategies. As the known oncomir, miR-17~92, is regulated by BCR-ABL fusion in chronic myeloid leukaemia, we investigated its role in BCR-ABL translocated ALL. miR-17~92-encoded miRNAs were significantly less abundant in BCR-ABL-positive as compared to -negative ALL-cells and overexpression of miR-17~19b triggered apoptosis in a BCR-ABL-dependent manner. Stable isotope labelling of amino acids in culture (SILAC) followed by liquid chromatography and mass spectroscopy (LC-MS) identified several apoptosis-related proteins including Bcl2 as potential targets of miR-17~19b. We validated Bcl2 as a direct target of this miRNA cluster in mice and humans, and, similar to miR-17~19b overexpression, Bcl2-specific RNAi strongly induced apoptosis in BCR-ABL-positive cells. Furthermore, BCR-ABL-positive human ALL cell lines were more sensitive to pharmacological BCL2 inhibition than negative ones. Finally, in a xenograft model using patient-derived leukaemic blasts, real-time, in vivo imaging confirmed pharmacological inhibition of BCL2 as a new therapeutic strategy in BCR-ABL-positive ALL. These data demonstrate the role of miR-17~92 in regulation of apoptosis, and identify BCL2 as a therapeutic target of particular relevance in BCR-ABL-positive ALL.
Object: Minimally invasive spine (MIS) procedures are increasingly being recognized as equivalent to open procedures with regard to clinical and radiographic outcomes. These techniques are also believed to result in less pain and disability in the immediate postoperative period. There are, however, little data to assess whether these procedures in combination with minimally invasive transforaminal interbody fusion (MI-TLIF) and percutaneous pedicle screw insertion are effective in complex cases of stenotic degenerative spondylolisthesis with severe facet joint osteoarthritis (FJO).
Methods: This study retrospectively reviewed all patients who underwent lumbar instrumentation, fusion and decompression for degenerative spondylolisthesis with severe stenosis and facet joint osteoarthritis (FJO) between June 2010 and June 2011. Blood loss, operative time and intraoperative complications were assessed in all surgically treated patients who were treated with MIS decompression, MI-TLIF and percutaneous transpedicular instrumentation. Clinical outcome was measured using the Oswestry Disability Index (ODI) and Visual Analogue Scale (VAS) for back pain, leg pain, and activity level. Satisfaction was assessed with VAS for satisfaction. Radiological follow-up includes x-ray films, computed tomography and in some cases magnetic tomography scan.
Results: Twenty four cases with severe stenotic changes accompanied by severe FJO were treated with minimally invasive procedure. The minimum follow-up was 6 months with a mean of 8 months. The mean preoperative ODI score was 46.8, decreasing to a mean of 23 postoperatively. The mean VAS leg and back pain scores were 67.5 improving to means of 25.8. Twenty one out of 24 cases experienced a clinical benefit according to VAS for satisfaction and ODI. Complications included wound healing disturbance (4%), CSF fistula (4%) and contralateral radiculopathy due to articular bone spurs (8%). The accuracy of pedicle screws was high and only one revision surgery was performed.
Conclusion: MIS for severe stenotic spondylolisthesis leads to adequate and safe decompression of lumbar stenosis and results in a highly significant reduction of symptoms and disability. MIS-TLIF and percutaneous pedicle screw insertion constitute a promising treatment alternative for patients with severe stenosis and facet joint osteoarthritis
In this manuscript a comprehensive coverage of recent developments in the drug therapy of vasospasm while providing the background information that neuroscientists need to understand its rationale. The range of new agents available for treatment of cerebral vasospasm is expanding rapidly along with rapid advances in pharmacology and physiology that are uncovering the mechanisms of this disease. Although there are many publications for treatment of cerebral vasospasm, most are focusing on different aspects of vasospasm treatment and many have limited value due to insufficient quality. Moreover, the complexity of this, in many cases deleterious condition, is enormous and the information needed to understand drug effects is accordingly often not readily available in a single source. A number of pharmacological and medical therapies are currently in use or being investigated in an attempt to reverse cerebral vasospasm, but only a few have proven to be useful. Current research efforts promise the eventual production of new medical therapies. At last, recommendations for the use of different treatment stages based on currently available clinical data are provided.
Background: Classical dance comprises gender specific movement tasks. There is a lack of studies which investigate work related traumatic injuries in terms of gender specific differences in detail.
Objective: To define gender related differences of occupational accidents.
Methods: Basis for the evaluation were occupational injuries of professional dancers from three (n = 785; f: n = 358, m: n = 427) state theatres.
Results: The incidence rate (0.36 per year) was higher in males (m: 0.45, f: 0.29). There were gender specific differences as to the localizations of injuries, particularly the spine region (m: 17.3%, f: 9.8%, p = 0.05) and ankle joint (m: 23.7%, f: 35.5%, p = 0.003). Compared to male dancers, females sustained more injuries resulting from extrinsic factors. Significant differences could specifically be observed with dance floors (m: 8.8%, f: 15.1%, p = 0.02). There were also significant gender differences observed with movement vocabulary.
Conclusion: The clearly defined gender specific movement activities in classical dance are reflected in occupational accidents sustained. Organisational structures as well as work environment represent a burden likewise to male and female dancers. The presented differences support the development of gender specific injury prevention measures.
Background: Only few studies deal with the workload of physical therapists and the health consequences, although this occupational group is quite important for the health care system in many industrialized countries (e.g. ca. 136 000 people are currently employed as physical therapists in Germany). Therefore, the current state of knowledge of work-related diseases and disorders of physical therapists is insufficient. The aim of the "Physical Therapist Cohort" (PTC) study is to analyze the association between work-related exposures and diseases among physical therapists in Germany. This article describes the protocol of the baseline assessment of the PTC study.
Methods/Design: A cross-sectional study will be conducted as baseline assessment and will include a representative random sample of approximately 300 physical therapists employed in Germany (exposure group), and a population-based comparison group (n = 300). The comparison group will comprise a sample of working aged (18–65 years) inhabitants of a German city. Variables of interest will be assessed using a questionnaire manual including questions regarding musculoskeletal, dermal, and infectious diseases and disorders as well as psychosocial exposures, diseases and disorders. In addition to subjective measures, a clinical examination will be used to objectify the questionnaire-based results (n = 50).
Discussion: The study, which includes extensive data collection, provides a unique opportunity to study the prospective association of work-related exposures and associated complaints of physical therapists. Baseline results will give first clues with regard to whether and how prevalent main exposures of physiotherapeutic work and typical work areas of physical therapists are associated with the development of work-related diseases. Thereby, this baseline assessment provides the basis for further investigations to examine causal relationships in accordance with a longitudinal design.
Nanoparticles (particles sized between 1 and 100 nanometers) are more and more used in all fields of science and medicine for their physicochemical properties. As gold has traditionally been considered as chemically inert and biocompatible, in particular, gold nanoparticles have been established as valuable tools in several areas of biomedical research. But in contrast to the multitude of studies that addressed the clinical use of gold nanoparticles, only little is known about potential toxicological effects such as induction of inflammatory immune responses, possible apoptotic cell death or developmental growth inhibition in embryos. Therefore the present study performed a systematic review of toxicological data, especially experimentally acquired data concerning in-vivo-toxicity, published in the PubMed. It can be stated that the data in this area of research is still largely limited. Especially, knowledge about size-, charge- and surface-chemistry dependent in-vivo-toxicity is needed to predict the hazard potential of auric nanoparticles (AuNPs) for humans.
T-cell receptor (TCR) polyclonal mature T cells are surprisingly resistant to oncogenic transformation after retroviral insertion of T-cell oncogenes. In a mouse model, it has been shown that mature T-cell lymphoma/leukemia (MTCLL) is not induced upon transplantation of mature, TCR polyclonal wild-type (WT) T cells, transduced with gammaretroviral vectors encoding potent T-cell oncogenes, into RAG1-deficient recipients. However, further studies demonstrated that quasi-monoclonal T cells treated with the same protocol readily induced MTCLL in the recipient mice. It has been hypothesized that in the TCR polyclonal situation, outgrowth of preleukemic cells and subsequent conversion to overt malignancy is suppressed through regulation of clonal abundances on a per-clone basis due to interactions between TCRs and self-peptide-MHC-complexes (spMHCs), while these mechanisms fail in the quasi-monoclonal situation. To quantitatively study this hypothesis, we applied a mathematical modeling approach. In particular, we developed a novel ordinary differential equation model of T-cell homeostasis, in which T-cell fate depends on spMHC-TCR-interaction-triggered stimulatory signals from antigen-presenting cells (APCs). Based on our mathematical modeling approach, we identified parameter configurations of our model, which consistently explain the observed phenomena. Our results suggest that the preleukemic cells are less competent than healthy competitor cells in acquiring survival stimuli from APCs, but that proliferation of these preleukemic cells is less dependent on survival stimuli from APCs. These predictions now call for experimental validation.
The neurophysiological changes associated with Alzheimer's Disease (AD) and Mild Cognitive Impairment (MCI) include an increase in low frequency activity, as measured with electroencephalography or magnetoencephalography (MEG). A relevant property of spectral measures is the alpha peak, which corresponds to the dominant alpha rhythm. Here we studied the spatial distribution of MEG resting state alpha peak frequency and amplitude values in a sample of 27 MCI patients and 24 age-matched healthy controls. Power spectra were reconstructed in source space with linearly constrained minimum variance beamformer. Then, 88 Regions of Interest (ROIs) were defined and an alpha peak per ROI and subject was identified. Statistical analyses were performed at every ROI, accounting for age, sex and educational level. Peak frequency was significantly decreased (p < 0.05) in MCIs in many posterior ROIs. The average peak frequency over all ROIs was 9.68 ± 0.71 Hz for controls and 9.05 ± 0.90 Hz for MCIs and the average normalized amplitude was (2.57 ± 0.59)·10(-2) for controls and (2.70 ± 0.49)·10(-2) for MCIs. Age and gender were also found to play a role in the alpha peak, since its frequency was higher in females than in males in posterior ROIs and correlated negatively with age in frontal ROIs. Furthermore, we examined the dependence of peak parameters with hippocampal volume, which is a commonly used marker of early structural AD-related damage. Peak frequency was positively correlated with hippocampal volume in many posterior ROIs. Overall, these findings indicate a pathological alpha slowing in MCI.
Ataxin-2 (ATXN2) is implicated mainly in mRNA processing. Some ATXN2 associates with receptor tyrosine kinases (RTK), inhibiting their endocytic internalization through interaction of proline-rich domains (PRD) in ATXN2 with SH3 motifs in Src. Gain of function of ATXN2 leads to neuronal atrophy in the diseases spinocerebellar ataxia type 2 (SCA2) and amyotrophic lateral sclerosis (ALS). Conversely, ATXN2 knockout (KO) mice show hypertrophy and insulin resistance. To elucidate the influence of ATXN2 on trophic regulation, we surveyed interactions of ATXN2 with SH3 motifs from numerous proteins and observed a novel interaction with Grb2. Direct binding in glutathione S-transferase (GST) pull-down assays and coimmunoprecipitation of the endogenous proteins indicated a physiologically relevant association. In SCA2 patient fibroblasts, Grb2 more than Src protein levels were diminished, with an upregulation of both transcripts suggesting enhanced protein turnover. In KO mouse embryonal fibroblasts (MEF), the protein levels of Grb2 and Src were decreased. ATXN2 absence by itself was insufficient to significantly change Grb2-dependent signaling for endogenous Ras levels, Ras-GTP levels, and kinetics as well as MEK1 phosphorylation, suggesting that other factors compensate for proliferation control. In KO tissue with postmitotic neurons, a significant decrease of Src protein levels is prominent rather than Grb2. ATXN2 mutations modulate the levels of several components of the RTK endocytosis complex and may thus contribute to alter cell proliferation as well as translation and growth.
In zahlreichen, in der Einleitung bereits näher beschriebenen Studien konnte anxiolytische Wirksamkeit des patentierten ätherischen Öls Silexan sowohl im Tiermodell, als auch am Menschen zur Therapie subsyndromaler und generalisierter Angsterkrankungen demonstriert werden.
Das Ziel der vorliegenden Dissertation war es, den zugrunde liegenden pharmakologischen Wirkmechanismus zu untersuchen. Nach eingehender Analyse der Targets klassischer Anxiolytika, richtete sich der Fokus auf spannungsabhängige Calciumkanäle, die die Bindungsstelle des Gabapentinoids Pregabalin enthalten. Die mögliche Modulation der Kanäle wurde an PC-Zellen, einem Modell neuronaler Vorläuferzellen, murinen Synaptosomen, aber auch in primären Neuronen der für die Genese der Angsterkrankungen relevanten Hirnareale Hippocampus und Cortex untersucht. Die Kanalexpression, sowie - distribution in den unterschiedlichen Geweben wurde charakterisiert und die Frage erörtert, ob Silexan spezifische Modulation eines bestimmten Kanalsubtyps vermittelt oder unspezifisch alle Kanäle dieser Gattung inhibiert. Um dies näher zu beleuchten wurden elektrophysiologische Messungen an transfizierten Zellen durchgeführt, die jeweils nur einen Subtyp der Familie spannungsabhängiger Calciumkanäle exprimieren. Zur weiteren Aufklärung des Wirkmechanismus wurde auch die mögliche Involvierung G-Protein gekoppelter Rezeptoren ermittelt.
Der zweite Teil der vorliegenden Untersuchung widmet sich der Klärung potentieller antidepressiver Wirkungen durch mögliche neurotrophe Effekte. Primäre hippocampale Neurone und PC12-Zellen wurden hierzu u.a. auf prä- und postsynaptische Marker, Ausdifferenzierungsmarker, sowie Neuritenwachstum hin analysiert.
Background: High-producer TGFβ1 genotypes are associated with severe lung disease in cystic fibrosis (CF), but studies combining IL-8, TNFα-, and TGFβ1(+genotype) levels and their impact on CF lung disease are scarce.
Aim: Assessing the relationship between TGFβ1, IL-8, and TNF-α and lung disease in CF in an exacerbation-free interval.
Methods: Twenty four patients delta F508 homozygous (median age 20.5 y, Shwachman score 75, FEV1(%) 83) and 8 controls (median age 27.5 y) were examined. TGFβ1 was assessed in serum and induced sputum (IS) by ELISA, for IL-8 and TNF-α by chemiluminescence in IS and whole blood. Genotyping was performed for TGFβ1 C−509T and T+869C utilizing RFLP.
Results: TGFβ1 in IS (CF/controls median 76.5/59.1 pg/mL, P < 0.074) was higher in CF. There was a negative correlation between TGFβ1 in serum and lung function (LF) (FEV1 (r = −0.488, P = 0.025), MEF 25 (r = −0.425, P = 0.055), and VC (r = −0.572, P = 0.007)). Genotypes had no impact on TGFβ1 in IS, serum, and LF. In IS TGFβ1 correlated with IL-8 (r = 0.593, P < 0.007) and TNF-α (r = 0.536, P < 0.018) in patients colonized by bacteria with flagellin.
Conclusion: TGFβ1 in serum not in IS correlates with LF. In patients colonized by bacteria with flagellin, TGFβ1 correlates with IL-8 and TNF-α in IS.
The Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO) here presents its updated recommendations for the treatment of documented fungal infections. Invasive fungal infections are a main cause of morbidity and mortality in cancer patients undergoing intensive chemotherapy regimens. In recent years, new antifungal agents have been licensed, and agents already approved have been studied in new indications. The choice of the most appropriate antifungal treatment depends on the fungal species suspected or identified, the patient’s risk factors (e.g., length and depth of neutropenia), and the expected side effects. This guideline reviews the clinical studies that served as a basis for the following recommendations. All recommendations including the levels of evidence are summarized in tables to give the reader rapid access to the information.
Background: The pro-inflammatory status of the elderly triggers most of the age-related diseases such as cancer and atherosclerosis. Atherosclerosis, the leading cause world wide of morbidity and death, is an inflammatory disease influenced by life-style and genetic host factors. Stimuli such as oxLDL or microbial ligands have been proposed to trigger inflammation leading to atherosclerosis. It has recently been shown that oxLDL activates immune cells via the Toll-like receptor (TLR) 4/6 complex. Several common single nucleotide polymorphisms (SNPs) of the TLR system have been associated with atherosclerosis. To investigate the role of TLR-6 we analyzed the association of the TLR-6 SNP Pro249Ser with atherogenesis.
Results: Genotyping of two independent groups with CAD, as well as of healthy controls revealed a significant association of the homozygous genotype with a reduced risk for atherosclerosis (odds ratio: 0.69, 95% CI 0.51-0.95, P = 0.02). In addition, we found a trend towards an association with the risk of restenosis after transluminal coronary angioplasty (odds ratio: 0.53, 95% CI 0.24-1.16, P = 0.12). In addition, first evidence is presented that the frequency of this protective genotype increases in a healthy population with age. Taken together, our results define a role for TLR-6 and its genetic variations in modulating the inflammatory response leading to atherosclerosis.
Conclusions: These results may lead to a better risk stratification, and potentially to an improved prophylactic treatment of high-risk populations. Furthermore, the protective effect of this polymorphism may lead to an increase of this genotype in the healthy elderly and may therefore be a novel genetic marker for the well-being during aging.
The leukemia-associated fusion protein RUNX1/ETO is generated by the chromosomal translocation t(8;21) which appears in about 12% of all de novo acute myeloid leukemias (AMLs). Essential for the oncogenic potential of RUNX1/ETO is the oligomerization of the chimeric fusion protein through the nervy homology region 2 (NHR2) within ETO. In previous studies, we have shown that the intracellular expression of peptides containing the NHR2 domain inhibits RUNX1/ETO oligomerization, thereby preventing cell proliferation and inducing differentiation of RUNX1/ETO transformed cells. Here, we show that introduction of a recombinant TAT-NHR2 fusion polypeptide into the RUNX1/ETO growth-dependent myeloid cell line Kasumi-1 results in decreased cell proliferation and increased numbers of apoptotic cells. This effect was highly specific and mediated by binding the TAT-NHR2 peptide to ETO sequences, as TAT-polypeptides containing the oligomerization domain of BCR did not affect cell proliferation or apoptosis in Kasumi-1 cells. Thus, the selective interference with NHR2-mediated oligomerization by peptides represents a challenging but promising strategy for the inhibition of the leukemogenic potential of RUNX1/ETO in t(8;21)-positive leukemia.
Purpose: Scientific evidence is limited regarding the long-term (>10 years) outcomes of large enough numbers of implants (>500) to allow for reliable comparison of subgroups. The purpose of this study was to analyze the outcomes of dental implants placed in an active University Clinic setting and followed for up to 20 years.
Materials and Methods: Data documenting the implant placement, prosthetic reconstruction, and annual follow-up of patients treated at Frankfurt University were extracted from a Structured Query Language database and patients’ written records and evaluated statistically.
Results: Between April of 1991 and May of 2011, 12,737 ANKYLOS® (DENTSPLY Implants Manufacturing GmbH, Mannheim, Germany) implants were placed in 4,206 patients for a variety of clinical indications. The Kaplan–Meier cumulative survival rate (CSR) was 93.3% after 204 months. Most of the failures (198/1.6%) occurred during the first year after implant placement and before prosthesis delivery. A significantly higher (p < .001) number of implants placed in the mandible and in hard quality bone failed than those placed in the maxilla or in weak and normal quality bone. Female patients had significantly higher CSRs (93.7% 204 months) than male patients (92.8% 204 months/p = .029). The implants showed low rates of peri-implant bone loss after 204 months (horizontal: 21 mm: 85.7%, vertical: 21 mm: 85.2%).
Conclusion: ANKYLOS dental implants followed for up to 20 years have high CSRs and low rates of peri-implant bone loss.
Objective: The aim of the study was to analyse the psychometric properties of the EQ-5D in patients with social phobia.
Methods: We used a sample of 445 patients with social phobia with five measurement points over a 30 month period. The discriminative ability of the EQ-5D was analysed by comparing the patients' responses with the general population and between different disease severity levels. For test-retest reliability we assessed the level of agreement in patients' responses over time, when there was no change in the Liebowitz Social Anxiety Scale (LSAS). Construct validity was analysed by identifying correlations of the EQ-5D with more specific instruments. For responsiveness we compared the means of EQ VAS/EQ-5D index anchored on improved (deteriorated) health status and computed effect sizes as well as a receiver operating characteristic (ROC) curve.
Results: Compared to the general population, patients with social phobia reported more problems in the dimensions "usual activities", "pain/discomfort", and "anxiety/depression" and less problems in "mobility" and "self-care". The EQ-5D was able to distinguish between different disease severity levels. The test-retest reliability was moderate (intraclass correlation coefficient > 0.6). Correlations between the EQ-5D and other instruments were mostly small except for correlations with Beck Depression Inventory. The EQ-5D index seemed to be more responsive than the EQ VAS, but with only medium effect sizes (0.5 < effect size < 0.8) in the British EQ-5D index and only significant in patients with improved health status. The ROC analysis revealed no significant results.
Conclusions: The EQ-5D was moderately reliable and responsive in patients with improved health status. Construct validity was limited.
Trial registration: Current controlled trials ISRCTN53517394.
Inhibitor of Apoptosis (IAP) proteins are a family of proteins with antiapoptotic functions that contribute to the evasion of apoptosis, a form of programed cell death. IAP proteins are expressed at high levels in a variety of human cancers including childhood acute leukemia. This elevated expression has been associated with unfavorable prognosis and poor outcome. Therefore, IAP proteins are currently exploited as therapeutic targets for cancer drug discovery. Consequently, small-molecule inhibitors or antisense oligonucleotides directed against IAP proteins have been developed over the last years. Indeed, IAP antagonists proved to exhibit in vitro and in vivo antitumor activities against childhood pediatric leukemia in several preclinical studies. Thus, targeting IAP proteins represents a promising molecular targeted strategy to overcome apoptosis resistance in childhood leukemia, which warrants further exploitation.
Scientists who are members of an editorial board have been accused of preferentially publishing their scientific work in the journal where they serve as editor. Reputation and academic standing do depend on an uninterrupted flow of published scientific work and the question does arise as to whether publication mainly occurs in the self-edited journal. This investigation was designed to determine whether editorial board members of five urological journals were more likely to publish their research reports in their own rather than in other journals. A retrospective analysis was conducted for all original reports published from 2001–2010 by 65 editorial board members nominated to the boards of five impact leading urologic journals in 2006. Publications before editorial board membership, 2001–2005, and publications within the period of time as an editorial board member, 2006–2010, were identified. The impact factors of the journals were also recorded over the time period 2001–2010 to see whether a change in impact factor correlated with publication locality. In the five journals as a whole, scientific work was not preferentially published in the journal in which the scientists served as editor. However, significant heterogeneity among the journals was evident. One journal showed a significant increase in the amount of published papers in the ‘own’ journal after assumption of editorship, three journals showed no change and one journal showed a highly significant decrease in publishing in the ‘own’ journal after assumption of editorship.
The membrane bound NADPH oxidase involved in the synthesis of reactive oxygen species (ROS) is a multi-protein enzyme encoded by CYBA, CYBB, NCF1, NCF2 and NCF4 genes. Growing evidence suggests a role of ROS in the modulation of signaling pathways of non-phagocytic cells, including differentiation and proliferation of B-cell progenitors. Transcriptional downregulation of the CYBB gene has been previously reported in cell lines of the B-cell derived classical Hodgkin lymphoma (cHL). Thus, we explored functional consequences of CYBB downregulation on the NADPH complex. Using flow cytometry to detect and quantify superoxide anion synthesis in cHL cell lines we identified recurrent loss of superoxide anion production in all stimulated cHL cell lines in contrast to stimulated non-Hodgkin lymphoma cell lines. As CYBB loss proved to exert a deleterious effect on the NADPH oxidase complex in cHL cell lines, we analyzed the CYBB locus in Hodgkin and Reed-Sternberg (HRS) cells of primary cHL biopsies by in situ hybridisation and identified recurrent deletions of the gene in 8/18 cases. Immunohistochemical analysis to 14 of these cases revealed a complete lack of detectable CYBB protein expression in all HRS cells in all cases studied. Moreover, by microarray profiling of cHL cell lines we identified additional alterations of NADPH oxidase genes including CYBA copy number loss in 3/7 cell lines and a significant downregulation of the NCF1 transcription (p=0.006) compared to normal B-cell subsets. Besides, NCF1 protein was significantly downregulated (p<0.005) in cHL compared to other lymphoma cell lines. Together this findings show recurrent alterations of the NADPH oxidase encoding genes that result in functional inactivation of the enzyme and reduced production of superoxide anion in cHL.
Introduction: We have recently described an increased lymphocytic infiltration rate in breast carcinoma tissue is a significant response predictor for anthracycline/taxane-based neoadjuvant chemotherapy (NACT). The aim of this study was to prospectively validate the tumor-associated lymphocyte infiltrate as predictive marker for response to anthracycline/taxane-based NACT.
Patients and Methods: The immunological infiltrate was prospectively evaluated in a total of 313 core biopsies from HER2 negative patients of the multicenter PREDICT study, a substudy of the neoadjuvant GeparQuinto study. Intratumoral lymphocytes (iTuLy), stromal lymphocytes (strLy) as well as lymphocyte-predominant breast cancer (LPBC) were evaluated by histopathological assessment. Pathological complete response (pCR) rates were analyzed and compared between the defined subgroups using the exact test of Fisher.
Results: Patients with lymphocyte-predominant breast cancer (LPBC) had a significantly increased pCR rate of 36.6%, compared to non-LPBC patients (14.3%, p<0.001). LPBC and stromal lymphocytes were significantly independent predictors for pCR in multivariate analysis (LPBC: OR 2.7, p = 0.003, strLy: OR 1.2, p = 0.01). The amount of intratumoral lymphocytes was significantly predictive for pCR in univariate (OR 1.2, p = 0.01) but not in multivariate logistic regression analysis (OR 1.2, p = 0.11).
Conclusion: Confirming previous investigations of our group, we have prospectively validated in an independent cohort that an increased immunological infiltrate in breast tumor tissue is predictive for response to anthracycline/taxane-based NACT. Patients with LPBC and increased stromal lymphocyte infiltration have significantly increased pCR rates. The lymphocytic infiltrate is a promising additional parameter for histopathological evaluation of breast cancer core biopsies.
Despite numerous clinical studies, which have investigated the therapeutic potential of repetitive transcranial magnetic stimulation (rTMS) in various brain diseases, our knowledge of the cellular and molecular mechanisms underlying rTMS-based therapies remains limited. Thus, a deeper understanding of rTMS-induced neural plasticity is required to optimize current treatment protocols. Studies in small animals or appropriate in vitro preparations (including models of brain diseases) provide highly useful experimental approaches in this context. State-of-the-art electrophysiological and live-cell imaging techniques that are well established in basic neuroscience can help answering some of the major questions in the field, such as (i) which neural structures are activated during TMS, (ii) how does rTMS induce Hebbian plasticity, and (iii) are other forms of plasticity (e.g., metaplasticity, structural plasticity) induced by rTMS? We argue that data gained from these studies will support the development of more effective and specific applications of rTMS in clinical practice.
Peripheral sensitization during inflammatory pain is mediated by a variety of endogenous proalgesic mediators including a number of oxidized lipids, some of which serve endogenous modulators of sensory TRP-channels. These lipids are eicosanoids of the arachidonic acid and linoleic acid pathway, as well as lysophophatidic acids (LPAs). However, their regulation pattern during inflammatory pain and their contribution to peripheral sensitization is still unclear. Here, we used the UVB-model for inflammatory pain to investigate alterations of lipid concentrations at the site of inflammation, the dorsal root ganglia (DRGs) as well as the spinal dorsal horn and quantified 21 lipid species from five different lipid families at the peak of inflammation 48 hours post irradiation. We found that known proinflammatory lipids as well as lipids with unknown roles in inflammatory pain to be strongly increased in the skin, whereas surprisingly little changes of lipid levels were seen in DRGs or the dorsal horn. Importantly, although there are profound differences between the number of cytochrome (CYP) genes between mice and rats, CYP-derived lipids were regulated similarly in both species. Since TRPV1 agonists such as LPA 18:1, 9- and 13-HODE, 5- and 12-HETE were elevated in the skin, they may contribute to thermal hyperalgesia and mechanical allodynia during UVB-induced inflammatory pain. These results may explain why some studies show relatively weak analgesic effects of cyclooxygenase inhibitors in UVB-induced skin inflammation, as they do not inhibit synthesis of other proalgesic lipids such as LPA 18:1, 9-and 13-HODE and HETEs.
Background: Published estimates on age-dependent frequency of diabetes in cystic fibrosis (CF) vary widely, and are based mostly on older data. However, CF treatment and prevention of comorbidities changed over recent years. In many studies, definition of cystic fibrosis-related diabetes (CFRD) is not in line with current guideline recommendations. Therefore, we evaluated age-dependent occurrence of glucose abnormalities and associated risk factors in CF patients who participated in a multicenter screening program using oral glucose tolerance tests (OGTT).
Methods: Between 2001 and 2010, 43 specialized CF centers from Germany and Austria serially performed 5,179 standardized OGTTs in 1,658 clinically stable, non-pregnant CF patients with no prior steroid medication or lung transplantation. Age-dependent occurrence of impaired fasting glucose (IFG), impaired glucose tolerance (IGT), IFG+IGT, one (DGT) or two consecutive (CFRD) diabetic OGTTs was analyzed, using Kaplan Meier curves. Cox proportional-hazards models were created to elucidate the influence of sex or underweight.
Results: At baseline/last OGTT, median age was 15.9 years/18.2 years and 30.6%/31.8% of patients were underweight. 25% of patients showed IFG at age 14.3 years; IGT at age 16.3 years; IFG+IGT combined at age 17.7 years. DGT was observed in 25% of patients at age 22.6 years; CFRD at age 34.5 years. Females had a 3.54 [95% CI 1.23–10.18] times higher risk for CFRD; risk for DGT was 2.21 [1.22–3.98] times higher. Underweight was a risk factor for IGT (HR [95% CI]: 1.38 [1.11–1.71]) and IFG+IGT (1.43 [1.11–1.83]), and in males also for DGT (1.49 [1.09–2.04]).
Conclusions/Significance: If confirmation of diabetes by a second test is required, as recommended in current guidelines, age at CFRD diagnosis was higher compared to most previous studies. However, known risk factors for glucose abnormalities in CF were confirmed. Confirmation of diabetic OGT by a repeat test is important for a consistent diagnosis of CFRD.
Background: Cannabinoid receptor 1 (CB1) is expressed in certain types of malignancies. An analysis of CB1 expression and function in Hodgkin lymphoma (HL), one of the most frequent lymphomas, was not performed to date.
Design and Methods: We examined the distribution of CB1 protein in primary cases of HL. Using lymphoma derived cell lines, the role of CB1 signaling on cell survival was investigated.
Results: A predominant expression of CB1 was found in Hodgkin-Reed-Sternberg cells in a vast majority of classical HL cases. The HL cell lines L428, L540 and KM-H2 showed strong CB1-abundance and displayed a dose-dependent decline of viability under CB1 inhibition with AM251. Further, application of AM251 led to decrease of constitutively active NFκB/p65, a crucial survival factor of HRS-cells, and was followed by elevation of apoptotic markers in HL cells.
Conclusions: The present study identifies CB1 as a feature of HL, which might serve as a potential selective target in the treatment of Hodgkin lymphoma.
Sequential dosing in chemosensitization : targeting the PI3K/Akt/mTOR pathway in neuroblastoma
(2013)
Breaking resistance to chemotherapy is a major goal of combination therapy in many tumors, including advanced neuroblastoma. We recently demonstrated that increased activity of the PI3K/Akt network is associated with poor prognosis, thus providing an ideal target for chemosensitization. Here we show that targeted therapy using the PI3K/mTOR inhibitor NVP-BEZ235 significantly enhances doxorubicin-induced apoptosis in neuroblastoma cells. Importantly, this increase in apoptosis was dependent on scheduling: while pretreatment with the inhibitor reduced doxorubicin-induced apoptosis, the sensitizing effect in co-treatment could further be increased by delayed addition of the inhibitor post chemotherapy. Desensitization for doxorubicin-induced apoptosis seemed to be mediated by a combination of cell cycle-arrest and autophagy induction, whereas sensitization was found to occur at the level of mitochondria within one hour of NVP-BEZ235 posttreatment, leading to a rapid loss of mitochondrial membrane potential with subsequent cytochrome c release and caspase-3 activation. Within the relevant time span we observed marked alterations in a ~30 kDa protein associated with mitochondrial proteins and identified it as VDAC1/Porin protein, an integral part of the mitochondrial permeability transition pore complex. VDAC1 is negatively regulated by the PI3K/Akt pathway via GSK3β and inhibition of GSK3β, which is activated when Akt is blocked, ablated the sensitizing effect of NVP-BEZ235 posttreatment. Our findings show that cancer cells can be sensitized for chemotherapy induced cell death – at least in part – by NVP-BEZ235-mediated modulation of VDAC1. More generally, we show data that suggest that sequential dosing, in particular when multiple inhibitors of a single pathway are used in the optimal sequence, has important implications for the general design of combination therapies involving molecular targeted approaches towards the PI3K/Akt/mTOR signaling network.
Vasoplegia is a severe complication after cardiac surgery. Within the last years the administration of nitric oxide synthase inhibitor methylene blue (MB) became a new therapeutic strategy. Our aim was to investigate the role of MB on transendothelial migration of circulating blood cells, the potential role of cyclic cGMP, eNOS and iNOS in this process, and the influence of MB on endothelial cell apoptosis. Human vascular endothelial cells (HuMEC-1) were treated for 30 minutes or 2 hours with different concentrations of MB. Inflammation was mimicked by LPS stimulation prior and after MB. Transmigration of PBMCs and T-Lymphocytes through the treated endothelial cells was investigated. The influence of MB upon the different subsets of PBMCs (Granulocytes, T- and B-Lymphocytes, and Monocytes) was assessed after transmigration by means of flow-cytometry. The effect of MB on cell apoptosis was evaluated using Annexin-V and Propidium Iodide stainings. Analyses of the expression of cyclic cGMP, eNOS and iNOS were performed by means of RT-PCR and Western Blot. Results were analyzed using unpaired Students T-test. Analysis of endothelial cell apoptosis by MB indicated a dose-dependent increase of apoptotic cells. We observed time- and dose-dependent effects of MB on transendothelial migration of PBMCs. The prophylactic administration of MB led to an increase of transendothelial migration of PBMCs but not Jurkat cells. Furthermore, HuMEC-1 secretion of cGMP correlated with iNOS expression after MB administration but not with eNOS expression. Expression of these molecules was reduced after MB administration at protein level. This study clearly reveals that endothelial response to MB is dose- and especially time-dependent. MB shows different effects on circulating blood cell-subtypes, and modifies the release patterns of eNOS, iNOS, and cGMP. The transendothelial migration is modulated after treatment with MB. Furthermore, MB provokes apoptosis of endothelial cells in a dose/time-dependent manner.
Functional responses of natural killer (NK) cells including eradication of “harmful” cells and modulation of immune responses are regulated by a broad variety of activating and inhibitory NK receptors. Whereas the leukocyte receptor complex (LRC) encodes for NK receptors of the immunoglobulin superfamily, genes of C-type lectin-like NK receptors are clustered in the mammalian natural killer gene complex (NKC). Besides the thoroughly studied C-type lectin-like receptors NKG2D, CD94/NKG2x, and members of the murine Ly49 subfamily, the NKC also encodes for NK receptors of the less characterized NKRP1 subfamily. The prototypic mouse NKRP1 receptor is Nkrp1c (also known as NK1.1), while human members of the NKRP1 subfamily are NKRP1A, NKp80, and NKp65. The latter are not straight homologs of mouse NKRP1 receptors, but share distinct subfamily-specific traits classifying them as members of the NKRP1 subfamily. Ligands of the human NKPR1 receptors are likewise C-type lectin-like glycoproteins belonging to the CLEC2 subfamily (i.e., LLT1, AICL, and KACL), and are encoded in the NKC in tight genetic linkage to their respective receptors. Similarly, certain members of the mouse NKRP1 subfamily interact with genetically coupled CLEC2 glycoproteins, while the reasons for this intriguing tight genetic linkage remain unknown. Recent studies provided new and unique insights into the expression, interaction, and signaling of NKRP1 receptors and their ligands, thereby substantially advancing our understanding of their function and biology. Here, we review our current knowledge on NKRP1 receptors and their genetically linked CLEC2 ligands with an emphasis on the human receptor/ligand pairs NKRP1A-LLT1, NKp80-AICL, and NKp65-KACL.
The efficient coding hypothesis posits that sensory systems of animals strive to encode sensory signals efficiently by taking into account the redundancies in them. This principle has been very successful in explaining response properties of visual sensory neurons as adaptations to the statistics of natural images. Recently, we have begun to extend the efficient coding hypothesis to active perception through a form of intrinsically motivated learning: a sensory model learns an efficient code for the sensory signals while a reinforcement learner generates movements of the sense organs to improve the encoding of the signals. To this end, it receives an intrinsically generated reinforcement signal indicating how well the sensory model encodes the data. This approach has been tested in the context of binocular vison, leading to the autonomous development of disparity tuning and vergence control. Here we systematically investigate the robustness of the new approach in the context of a binocular vision system implemented on a robot. Robustness is an important aspect that reflects the ability of the system to deal with unmodeled disturbances or events, such as insults to the system that displace the stereo cameras. To demonstrate the robustness of our method and its ability to self-calibrate, we introduce various perturbations and test if and how the system recovers from them. We find that (1) the system can fully recover from a perturbation that can be compensated through the system's motor degrees of freedom, (2) performance degrades gracefully if the system cannot use its motor degrees of freedom to compensate for the perturbation, and (3) recovery from a perturbation is improved if both the sensory encoding and the behavior policy can adapt to the perturbation. Overall, this work demonstrates that our intrinsically motivated learning approach for efficient coding in active perception gives rise to a self-calibrating perceptual system of high robustness.
Genetic or pharmacological ablation of toll-like receptor 2 (TLR2) protects against myocardial ischemia/reperfusion injury (MI/R). However, the endogenous ligand responsible for TLR2 activation has not yet been detected. The objective of this study was to identify HMGB1 as an activator of TLR2 signalling during MI/R. C57BL/6 wild-type (WT) or TLR2(-/-)-mice were injected with vehicle, HMGB1, or HMGB1 BoxA one hour before myocardial ischemia (30 min) and reperfusion (24 hrs). Infarct size, cardiac troponin T, leukocyte infiltration, HMGB1 release, TLR4-, TLR9-, and RAGE-expression were quantified. HMGB1 plasma levels were measured in patients undergoing coronary artery bypass graft (CABG) surgery. HMGB1 antagonist BoxA reduced cardiomyocyte necrosis during MI/R in WT mice, accompanied by reduced leukocyte infiltration. Injection of HMGB1 did, however, not increase infarct size in WT animals. In TLR2(-/-)-hearts, neither BoxA nor HMGB1 affected infarct size. No differences in RAGE and TLR9 expression could be detected, while TLR2(-/-)-mice display increased TLR4 and HMGB1 expression. Plasma levels of HMGB1 were increased MI/R in TLR2(-/-)-mice after CABG surgery in patients carrying a TLR2 polymorphism (Arg753Gln). We here provide evidence that absence of TLR2 signalling abrogates infarct-sparing effects of HMGB1 blockade.
Background and study objective: Focused lung ultrasound (LUS) examinations are important tools in critical care medicine. There is evidence that LUS can be used for the detection of acute thoracic lesions. However, no validated training method is available. The goal of this study was to develop and assess an objective structured clinical examination (OSCE) curriculum for focused thorax, trachea, and lung ultrasound in emergency and critical care medicine (THOLUUSE).
Methods: 39 trainees underwent a one-day training course in a prospective educational study, including lectures in sonoanatomy and -pathology of the thorax, case presentations, and hands-on training. Trainees' pre- and posttest performances were assessed by multiple choice questionnaires, visual perception tests by interpretation video clips, practical performance of LUS, and identification of specific ultrasound findings.
Results: Trainees postcourse scores of correct MCQ answers increased from 56 ± 4% to 82 ± 2% (mean± SD; P < 0.001); visual perception skills increased from 54 ± 5% to 78 ± 3% (P < 0.001); practical ultrasound skills improved, and correct LUS was performed in 94%. Subgroup analysis revealed that learning success was independent from the trainees' previous ultrasound experience.
Conclusions: THOLUUSE significantly improves theoretical and practical skills for the diagnosis of acute thoracic lesions. We propose to implement THOLUUSE in emergency medicine training.
Smoking cigarettes throughout pregnancy is one of the single most important avoidable causes of adverse pregnancy outcomes and it represents the first major environmental risk of the unborn. If compared with other risk factors in the perinatal period, exposure to tobacco smoke is considered to be amongst the most harmful and it is associated with high rates of long and short term morbidity and mortality for mother and child. A variety of adverse pregnancy outcomes are linked with cigarette consumption before and during pregnancy. Maternal prenatal cigarette smoke disturbs the equilibrium among the oxidant and antioxidant system, has negative impact on the genetic and cellular level of both mother and fetus and causes a large quantity of diseases in the unborn child. These smoking-induced damages for the unborn offspring manifest themselves at various times in life and for most only a very limited range of causal treatment exists. Education, support and assistance are of high importance to decrease maternal and fetal morbidity and mortality, as there are few other avoidable factors which influence a child's health that profoundly throughout its life. It is imperative that smoking control should be seen as a public health priority.
In the past century, scientists have realized that venoms are a source of a number of natural substances presenting a wide range of pharmacological properties and often displaying a high specificity for their targets. Thus, the field of toxinology came into being, which is defined as the study of toxic substances of biological origin. Toxins are found in a wide variety of animals, including fish, cone snails, scorpions, snakes, and even some mammals. To be classified as venom, these must contain substances, i.e. toxins, which disturb physiological processes and must be deliberately delivered to the target animal. Snakes have evolved one of the most sophisticated mechanisms for venom delivery. Envenomation by snakebite can induce and inhibit aggregation/agglutination of platelets as well as inhibit/activate hemostasis, but also disrupt other physiological functions via neurotoxins and angioneurin growth factors. Snake venoms contain a substantial amount of C-type lectin-related proteins (CLRPs) which are known to function, notably, as integrin inhibitors. CLRPs are heterodimers composed of homologous α and β subunits which can assemble either covalently or noncovalently to oligomers, resulting in αβ, (αβ)2 and (αβ)4 structures. Some of the main targets of CLRPs are membrane receptors, coagulation factors, and proteins essential to hemostasis. The platelet collagen receptors GPVI and α2β1 integrin as well as the von Willebrand factor receptor GPIb play important roles in platelet activation and aggregation and are considered main targets of antithrombotic drugs. In this thesis, the integrin α2β1 is particularly considered as it is the sole collagen-binding integrin on platelets. Reduced expression of this platelet receptor results in dysfunction of platelet responses. Equivalently, overexpression of α2β1 integrin results in an increased risk of thrombosis. As a result, selective inhibitors of the collagen-α2β1 interaction could give rise to effective antithrombotic drugs. Integrins are large receptors which mediate cell-cell contacts and the binding of cells to the extracellular matrix (ECM). Therefore, they play a role in physiological processes, e.g. hemostasis and immunity, as well as in pathological processes, e.g. tumor angiogenesis and atherosclerosis. 18 α and 8 β integrin subunits, with nine α subunits containing an additional A domain, associate non-covalently to form 24 heterodimers with distinct binding specificities. Integrin collagen receptors are a subclass of four receptors which all utilize the β1 subunit. The α2β1 integrin is a collagen-binding receptor expressed not only on platelets, but also on endothelial and epithelial cells. Consequently, this integrin is also essential for cell adhesion and migration playing a role in angiogenesis as well as tumor metastasis. To date, there are five known antagonists of α2β1 integrin: EMS16, rhodocetin, vixapatin, and most recently rhinocetin and flavocetin-A. The first four have been shown to be specific for the integrin α2A domain, the major collagen-binding domain. All these antagonists are CLRPs and present new leads for drug design. In the past few years, many insights into the structure and function of rhodocetin were obtained. Monoclonal antibodies proved to be advantageous in disclosing this information, making them not only useful as therapeutic agents, but also as tools for protein characterization. The venom of the Vipera palaestinae snake was recently shown to contain an α2β1 integrin inhibitor, which prevented the integrin from binding collagen. This inhibitor, called vixapatin, was the initial focus of this dissertation. Vixapatin’s interaction with the α2β1 integrin needed further characterization on a molecular and cellular level to assess its medical potential and monoclonal antibodies were to be used as a tool. Originally, vixapatin had been isolated by reversed-phase high-performance liquid chromatography. To avoid the stringency of this method, for this study, it was replaced with gentler chromatographic methods. First, the α2β1 integrin inhibitor was isolated from the crude snake venom with affinity chromatography using the α2A domain as bait, establishing a method to quickly screen venoms for α2β1-binding proteins which affect the collagenintegrin interaction. The applicability of this method to other snake venoms was shown by isolating an α2A domain-specific toxin from the venom of Trimeresurus flavoviridis. To allow further characterization of both these toxins, gel filtration and ion exchange chromatography were employed to purify the protein without the α2A domain. These classical protein purification methods resulted in similar separation patterns of both the V. palaestinae and T. flavoviridis venom proteins. Purified proteins exhibiting the potential of inhibiting integrinbinding to collagen were analyzed by two-dimensional gel electrophoresis. Both VP-i and flavocetin-A, the integrin inhibitors from V. palaestinae and T. flavoviridis, respectively, were shown to have more complex structures than was evident from the purification. Each consisted of four low-molecular-weight proteins which assembled into two bands (for VP-i) or one single band (for flavocetin-A) under non-reducing conditions. Mass spectrometry analyses revealed VP-i to belong to the family of CLRPs, just like vixapatin does. However, these two proteins differed in their primary sequences and only showed homology to one another. The toxin purified from T. flavoviridis revealed this toxin to be flavocetin-A, a heterodimeric CLRP which had so far only been shown to have GPIb-binding activity. At the time of flavocetin-A’s purification, flavocetin-B was co-purified; flavocetin-B consists of the same two α and β subunits, plus an additional γ subunit. As no sequence information is known to date for the γ subunit, it may be one of the additional proteins purified here, along with an additional δ subunit. Therefore, the toxin isolated here may actually consist of four different subunits forming a tetramer of two different heterodimers, generating an (αβ)2(γδ)2 structure. This proposed (αβ)2(γδ)2 flavocetin-A structure has binding sites for both α2β1 integrin and GPIb, with no sterical overlap, as shown by affinity chromatography using the α2A domain and the extracellular domain of the GPIb receptor. The potential of VP-i and flavocetin-A to inhibit integrin-binding to type I collagen was shown during purification: Both toxins efficiently bind to the integrin α2A domain; also, VP-i and vixapatin bind to the A domain with the same affinity. Surface plasmon resonance showed the interaction of flavocetin-A with the α2β1 integrin to be extremely strong and association to be very fast. Furthermore, both toxins were shown to inhibit binding of the wildtype integrin to collagen: VP-i and flavocetin-A acted antagonistically on cell adhesion and cell migration. Initially, the interaction between VP-i and α2β1 integrin was to be further characterized with the help of monoclonal antibodies. However, this proved problematic, the procedure requiring various optimizations. Although, after expert consultation, some monoclonal antibodies could be obtained, the cells were extremely sensitive and gave unsatisfactory results when tested as detection tools in Western blot and immunoassays. Concluding, two novel α2β1 integrin inhibitors were discovered: VP-i and flavocetin-A, which were purified using the same procedure and which have similar functions. Both are Ctype lectin-related proteins which effectively inhibit cell adhesion and migration. This underlines that nature has instrumentalized CLRPs to specifically inhibit α2β1 integrin. Further characterization of VP-i and flavocetin-A will be able to provide leads for future drug development.
Persistent neuropathic pain is a frequent consequence of peripheral nerve injuries, particularly in the elderly. Using the IntelliCage we studied if sciatic nerve injury obstructed learning and memory in young and aged mice, each in wild type and progranulin deficient mice, which develop premature signs of brain aging. Both young and aged mice developed long-term nerve injury-evoked hyperalgesia and allodynia. In both genotypes, aged mice with neuropathic pain showed high error rates in place avoidance acquisition tasks. However, once learnt, these aged mice with neuropathic pain showed a significantly stronger maintenance of the aversive memory. Nerve injury did not affect place preference behavior in neither genotype, neither in young nor aged mice. However, nerve injury in progranulin deficient mice impaired the learning of spatial sequences of awarded places, particularly in the aged mice. This task required a discrimination of clockwise and anti-clockwise sequences. The chaining failure occurred only in progranulin deficient mice after nerve injury, but not in sham operated or wildtype mice, suggesting that progranulin was particularly important for compensatory adaptations after nerve injury. In contrast, all aged mice with neuropathic pain, irrespective of the genotype, had a long maintenance of aversive memory suggesting a negative alliance and possibly mutual aggravation of chronic neuropathic pain and aversive memory at old age.
Gegenstand dieser Arbeit ist die Untersuchung der Genexpression der axonalen wachstumsassoziierten Proteine NAP-22, GAP-43 und CAP-23 in den dopaminergen Neuronen der Substantia nigra pars compacta (SNc), einer im Mesencephalon gelegenen Zellregion, relativ zu der Genexpression eines Referenzgens. Als Versuchstiere dienten sechs Monate alte, männliche CB6F1 Wildtypmäuse sowie sechs Monate alte, männliche CAP-23 transgene (CAP-23tg) Tiere, die das wachstumsassoziierte Protein CAP-23 überexprimieren. Die dopaminergen Zellen der SNc wurden zunächst morphologisch charakterisiert und ihre Ausdehnung im Mittelhirn durch alternierende Immunfärbungen der Tyrosinhydroxylase, einem Schlüsselenzym der Dopaminsynthese, sowie Toluidinblaufärbungen ermittelt. Anschließend wurden die Neurone durch die Methode der Lasermikrodissektion (LMD) im Zellverband isoliert. Hierfür war die Optimierung der Toluidinblaufärbung erforderlich, mit dem Ziel, sowohl eine gute Färbung der Neurone als auch eine hohe RNA-Nativität zu erzielen. Die RNA wurde isoliert und nach Integritätsprüfung in cDNA umgeschrieben. Daraufhin erfolgte die Analyse der Genexpression der beschriebenen Gene durch die quantitative Echtzeit-Polymerase-Kettenreaktion (qRT-PCR). Dabei war feststellbar, dass das Transgen Cap-23 in den transgenen Tieren stärker exprimiert wird als das Endogen Nap-22. Es zeigte sich jedoch kein signifikanter Unterschied der Expression von endogenem Nap-22 und endogenem Gap-43 in den CAP-23tg Tieren im Vergleich zu der Expression in den Wildtypmäusen. Das bedeutet, dass die Überexpression von Cap-23 in den transgenen Tieren die Expression der mRNA der beiden endogenen wachstumsassoziierten Proteine NAP-22 und GAP-43 nicht beeinflusst. Auf Grundlage der in dieser Arbeit vorgelegten Ergebnisse soll in Folgeexperimenten untersucht werden, inwieweit die Überexpression von CAP-23 die Reorganisationsfähigkeit dopaminerger Neuronen der SNc nach einer Schädigung beeinflusst, wie sie zum Beispiel beim Menschen im Verlauf des Morbus Parkinson beobachtet wird.
Abdominale Aortenaneurysmen sind in Industrienationen eine häufige Erkrankung der Personengruppe über 65 Jahre. Diese Dilatationen der abdominalen Aorta zeichnen sich durch eine lokale Inflammation aus, die mit der Infiltration von Immunzellen, dem Verlust von glatten vaskulären Muskelzellen und der Degeneration der extrazellulären Matrix einhergeht. Ursprünglich als Symptom einer Atherosklerose angesehen, sind die Ursachen dieser progressiv verlaufenden Erkrankung nach wie vor nicht vollständig verstanden; obwohl steigendes Alter, männliches Geschlecht, genetische Prädisposition, Rauchen und ein zuvor erlittener Myocardinfarkt als Risikofaktoren identifiziert werden konnten. Der lange Zeit asymptomatische Krankheitsverlauf, die Gefahr einer Ruptur mit häufig letalen Folgen und der Mangel einer effizienten pharmakologischen Therapie machen eine weitere Untersuchung dieser Erkrankung unabdingbar.
Diltiazem ist ein Inhibitor spannungssensitiver L Typ-Calciumkanäle, der seit über 25 Jahren zur Behandlung von arterieller Hypertonie, verschiedener Arrhythmien und Angina pectoris verwendet wird. Im Rahmen der vorliegenden Arbeit sollte untersucht werden, ob Diltiazem auch einen antianeurysmatischen Effekt besitzt. Eine vierwöchige subcutane Infusion des blutdrucksteigernden Hormons Angiotensin II führte nach vier Wochen zur Bildung abdominaler Aortenaneurysmen, sowie zu atherosklerotischen Gefäßveränderungen der thorakalen Aorta Apolipoprotein E (ApoE)-defizienter Mäuse. Eine parallele Therapie mit Diltiazem über das Trinkwasser konnte diese Entwicklung unabhängig vom arteriellen Blutdruck und damit unabhängig von der antihypertensiven Wirkung verhindern. Im Aortenbogen Diltiazem-behandelter Tiere konnte im Rahmen dieses in vivo-Modells nach sechs Tagen eine deutlich geringere lokale Expression proinflammatorischer Cytokine, wie Tumornekrosefaktor-a, Interleukin-1ß (IL1B) und Interleukin-6 (IL6), Chemokine, wie CCL2, und degenerativer Proteasen, wie der Matrix-Metalloprotease 9 (MMP9), festgestellt werden. Dies war die Folge einer reduzierten Anzahl von Macrophagen in der Gefäßwand. Zirkulierende proinflammatorische Cytokine, wie CCL12, konnten im Serum teilweise ebenfalls vermindert nachgewiesen werden.
Obwohl die antihypertensive Wirkung von Diltiazem in glatten vaskulären Muskelzellen vermittelt wird, war es nicht möglich, die Angiotensin II-induzierte Produktion von promigratorischem CCL2 und proinflammatorischem IL6 in isolierten Aortenringen ApoE-defizienter Mäuse oder in glatten vaskulären Muskelzellen der Ratte zu reduzieren. Diltiazem war zudem nicht in der Lage, die CCL2-induzierte Migration proinflammatorischer Ly6C+-Monocyten in vivo zu unterbinden. In isolierten peritonealen Macrophagen ApoE-defizienter Mäuse dagegen, konnte die IL6 induzierte Expression von IL1B- und CCL12-mRNA durch eine Inkubation mit Diltiazem verhindert werden. In der RAW264.7-Zelllinie, die morphologische und funktionelle Merkmale von Monocyten und Macrophagen aufweist, konnte die Dilitiazem-sensitive IL6-induzierte Expression von IL1B-mRNA in vitro ebenfalls nachgewiesen werden. Eine Stimulation mit IL6 war in diesen Zellen jedoch nicht ausreichend, um die Sekretion von IL1B-Protein auszulösen.
Thorakales Aortengewebe wies im Vergleich mit RAW264.7-Zellen eine veränderte Ausstattung spannungssensitiver Calciumkanäle auf. In letzteren fanden sich keine muskelzellspezifischen L-Typ-Calciumkanäle (CACNA1C), aber eine relevante Expression neuronaler P/Q-Typ-Calciumkanäle (CACNA1A). Mittels fluorimetrischer Bestimmung mit Fura-2AM konnte jedoch festgestellt werden, dass die intrazelluläre Calciumkonzentration Diltiazem-behandelter RAW264.7-Zellen unverändert war und der antiinflammatorische Effekt somit calciumunabhängig vermittelt wurde.
Diltiazem war nicht in der Lage, eine Lipopolysaccharid (LPS)-bedingte Inflammation in RAW264.7-Zellen zu unterbinden. Weder die LPS-induzierte Sekretion von IL1B Protein, noch die nucleäre Translokation des Transkriptionsfaktors NF-?B oder die Aktivierung des NF-?B-Promotors konnten durch eine Inkubation der Zellen mit Diltiazem verhindert werden. Diltiazem reduzierte jedoch, die IL6-induzierte Aktivierung des AP 1-Promotors unabhängig von der MAPK1-Phosphorylierung oder der Phosphorylierung und nucleären Translokation des Transkriptionsfaktors STAT3 zu unterbinden. Eine Unterdrückung von c-Jun N-terminale Kinase JNK- oder p38 Proteinkinase-vermittelten Signalwegen ist damit wahrscheinlich.
Das Pirinixinsäurederivat LP105 ist ein neuer Inhibitor der Arachidonat-5-Lipoxygenase (LOX5), der im Rahmen dieser Arbeit erstmals in vivo auf seine antianeurysmatischen Eigenschaften hin untersucht wurde. LOX5 katalysiert die Reaktion von Arachidonsäure zu Leukotrien A4 und kontrolliert damit einen wichtigen Schritt in der Synthese proinflammatorischer Leukotriene. LP105 war im Tiermodell nicht in der Lage die Angiotensin II-induzierte Bildung abdominaler Aortenaneurysmen in ApoE-defizienten Mäusen komplett zu unterbinden, führte aber über die Reduktion der vaskulären Inflammation zu einer deutlich verringerten Krankheitslast. LP105 selbst beeinflusste die mRNA-Expression verschiedener Enzyme des Arachidonsäuremetabolismus nicht, verstärkte jedoch durch die Blockade von LOX5 die Metabolisierung von Arachidonsäure über Arachidonat-15-Lipoxygenase und Cytochrom P450-Enzyme.
Eine Infektion mit dem Hepatitis B Virus (HBV) kann bei 5-10 % der infizierten Erwachsenen und 70-90 % der infizierten Kinder chronisch verlaufen. Trotz einer verfügbaren Impfung gegen die Erkrankung sind heute nach Angaben der WHO weltweit etwa 350 Mio. Menschen chronisch HBV-infiziert [Lupberger and Hildt, 2007, Hollinger and Liang, 2001]. In 5-10 % der Fälle führt eine chronische Infektion zu einer Leberfibrose und Zirrhose, welche letztlich zur Ausbildung eines hepatozellulären Karzinoms (HCC) führen kann. HCCs sind die dritthäufigste karzinomassoziierte Todesursache weltweit [Blum, 2005]. Um Therapien gegen eine HBV-Infektion und das damit erhöhte Risiko einer HCC-Entstehung entwickeln zu können, müssen die einzelnen Schritte des HBV-Replikationszyklus verstanden sein. Wesentliche Schritte der frühen Infektionsphase, insbesondere der Rezeptor bzw. Rezeptorkomplex, welcher den Zelleintritt des Virus vermittelt sowie der Transport des Virusgenoms in den Zellkern, sind bisher noch unklar. Auch der Exportprozess und die Freisetzung der Viruspartikel ist bisher noch nicht im Detail verstanden. Es ist jedoch bekannt, dass die Viruspartikel unter Nutzung der zellulären ESCRT (endosomal sorting complex required for transport)-Maschinerie aus der Zelle freigesetzt werden [Lambert et al., 2007]. Auf der Suche nach Faktoren, die in diese Vorgänge involviert sind, konnte in dieser Arbeit das vesikeltransportassoziierte Protein α-Taxilin identifiziert werden. Der Einfluss von HBV auf die α-Taxilin-Bildung und seine mögliche Beteiligung am viralen Export wurden dabei näher charakterisiert. In HBV-positiven Zellen konnte in vivo und in vitro eine signifikante Steigerung der α-Taxilin-Expression nachgewiesen werden. Diese wird hierbei durch die HBV-Proteine HBx und LHBs über den Raf/Mek/Erk-Signalweg induziert [Glatzel, 2011]. Mithilfe von knockdown-Experimenten konnte beobachtet werden, dass α-Taxilin für den Export der Viruspartikel, nicht aber für den Export subviraler Partikel (SVPs) essentiell ist. Der Export der Virionen findet hierbei über das ESCRT-System statt. Den HBV-Strukturproteinen fehlen jedoch die für die Interaktion mit dem ESCRT-System essentiellen late-Domänen. Die Proteinstruktur von α-Taxilin dagegen weist diese late-Domänen auf. In dieser Arbeit konnte diese interaktionsvermittelnde Funktion von α-Taxilin zwischen dem Virus und dem ESCRT-System charakterisiert werden. Über eine Interaktion von α-Taxilin mit dem viralen LHBs-Protein auf der einen Seite und der tsg101-Komponente des ESCRT-I-Komplexes auf der anderen Seite agiert α-Taxilin als eine Art Linker zwischen dem ESCRT-System und HBV.
Darüber hinaus wurde Annexin A5 als zellulärer Interaktionspartner für α-Taxilin identifiziert [Röttger, 2011]. Es dirigiert α-Taxilin in einer Art shuttle-Funktion auf die Zellmembran suszeptibler Zellen und bindet es an deren Zelloberfläche. Diese Exposition von α-Taxilin nimmt während der Dedifferenzierung in Korrelation mit dem Suszeptibilitätsverlust primärer Hepatozyten ab. Eine Maskierung von α-Taxilin durch eine vorherige Inkubation der Zellen mit α-Taxilin-spezifischen Antikörpern konnte die Bindung und die Aufnahme der Viren inhibieren. Überexpressionsstudien bestätigten die essentielle Rezeptorfunktion von α-Taxilin. Die verstärkte Produktion von α-Taxilin führte zur Suszeptibilität der Zellen. Auch die Speziesspezifität der Bindung zwischen humanem α-Taxilin und HBV konnte in einem Co-Immunpräzipitationsexperiment mit den rezeptorbindenden Domänen von HBV, WHV und DHBV identifiziert werden.
In der vorliegenden Arbeit konnte somit zum ersten Mal eine Rezeptorfunktion von α-Taxilin bei der Aufnahme von HBV in die Wirtszelle nachgewiesen werden. Darüber hinaus schreiben die in dieser Arbeit gemachten Beobachtungen α-Taxilin eine essentielle Funktion für die Vermittlung des ESCRT-abhängigen Exports der Virionen aus der Zelle zu. Die hierbei gewonnen Erkenntnisse sind von hoher Relevanz für die weitere Erforschung der HBV-assoziierten Pathogenese und die Etablierung eines in vivo Infektions-Modells.
Die phylogenetisch hochkonservierte Jak/Stat‐Signaltransduktionskaskade repräsentiert eines der zentralen Säulen zellulärer Signalübertragung eukaryotischer Organismen. Ubiquitär im Organismus exprimiert und über eine Vielzahl von Zytokinen, Hormonen und Wachstumsfaktoren aktiviert, sind Stat‐Transkriptionsfaktoren maßgeblich an dem Erhalt der Physiologie und Homöostase von Organen und Geweben beteiligt. So sind die Mitglieder Stat5A und Stat5B (als homologe Proteine im Verbund als Stat5 bezeichnet) entscheidende Regulatoren des Immunsystems und der Hämatopoese, der Funktion und Entwicklung des Prostata‐ und Brustdrüsengewebes (Mammogenese) oder bestimmter Funktionen der Leber. Wie auch Stat3, konnten Stat5 Proteine in aberrant aktiver Form in verschiedensten Typen und Stadien humaner Tumore nachgewiesen werden, wo sie über die Expression ihrer Zielgene sowie über weitere nicht‐kanonische Funktionen im Zytoplasma und im Zellkern einer fortschreitend malignen Entartung entscheidend beitragen. Als Folge der Unterstützung essentieller Tumorgenese‐
Mechanismen, wie gesteigertes Zellwachstum, Apoptosehemmung, Migration und Metastasierung, Sauerstoff‐unabhängiger Energiestoffwechsel, Angiogenese oder Umgehung der Immunabwehr, entwickeln Tumore häufig eine Abhängigkeit gegenüber der gesteigerten Aktivität dieser Vertreter der Stat‐Proteinfamilie und reagieren mit einem Wachstumsstopp und Apoptoseinduktion auf ihre Inhibierung. Perspektivisch stellt die gezielte Interferenz mit aberranten, Tumortyp‐spezifischen Stat5‐Aktivitäten einen relevanten Ansatz in der personalisierten Therapie Stat5‐abhängiger Tumore, vorrangig leukämischen Ursprungs, dar. ...
The signal transducer and activator of transcription Stat5 is transiently activated by growth factor and cytokine signals in normal cells, but its persistent activation has been observed in a wide range of human tumors. Aberrant Stat5 activity was initially observed in leukemias, but subsequently also found in carcinomas. We investigated the importance of Stat5 in human tumor cell lines. shRNA mediated downregulation of Stat5 revealed the dependence of prostate and breast cancer cells on the expression of this transcription factor. We extended these inhibition studies and derived a peptide aptamer (PA) ligand, which directly interacts with the DNA-binding domain of Stat5 in a yeast-two-hybrid screen. The Stat5 specific PA sequence is embedded in a thioredoxin (hTRX) scaffold protein. The resulting recombinant protein S5-DBD-PA was expressed in bacteria, purified and introduced into tumor cells by protein transduction. Alternatively, S5-DBD-PA was expressed in the tumor cells after infection with a S5-DBD-PA encoding gene transfer vector. Both strategies impaired the DNA-binding ability of Stat5, suppressed Stat5 dependent transactivation and caused its intracellular degradation. Our experiments describe a peptide based inhibitor of Stat5 protein activity which can serve as a lead for the development of a clinically useful compound for cancer treatment.
Introduction: We examined if a combination of proliferation markers and estrogen receptor (ER) activity could predict early versus late relapses in ER-positive breast cancer and inform the choice and length of adjuvant endocrine therapy.
Methods: Baseline affymetrix gene-expression profiles from ER-positive patients who received no systemic therapy (n = 559), adjuvant tamoxifen for 5 years (cohort-1: n = 683, cohort-2: n = 282) and from 58 patients treated with neoadjuvant letrozole for 3 months (gene-expression available at baseline, 14 and 90 days) were analyzed. A proliferation score based on the expression of mitotic kinases (MKS) and an ER-related score (ERS) adopted from Oncotype DX® were calculated. The same analysis was performed using the Genomic Grade Index as proliferation marker and the luminal gene score from the PAM50 classifier as measure of estrogen-related genes. Median values were used to define low and high marker groups and four combinations were created. Relapses were grouped into time cohorts of 0-2.5, 0-5, 5-10 years.
Results: In the overall 10 years period, the proportional hazards assumption was violated for several biomarker groups indicating time-dependent effects. In tamoxifen-treated patients Low-MKS/Low-ERS cancers had continuously increasing risk of relapse that was higher after 5 years than Low-MKS/High-ERS cancers [0 to 10 year, HR 3.36; p = 0.013]. High-MKS/High-ERS cancers had low risk of early relapse [0-2.5 years HR 0.13; p = 0.0006], but high risk of late relapse which was higher than in the High-MKS/Low-ERS group [after 5 years HR 3.86; p = 0.007]. The High-MKS/Low-ERS subset had most of the early relapses [0 to 2.5 years, HR 6.53; p < 0.0001] especially in node negative tumors and showed minimal response to neoadjuvant letrozole. These findings were qualitatively confirmed in a smaller independent cohort of tamoxifen-treated patients. Using different biomarkers provided similar results.
Conclusions: Early relapses are highest in highly proliferative/low-ERS cancers, in particular in node negative tumors. Relapses occurring after 5 years of adjuvant tamoxifen are highest among the highly-proliferative/high-ERS tumors although their risk of recurrence is modest in the first 5 years on tamoxifen. These tumors could be the best candidates for extended endocrine therapy.
Introduction: Langerhans Cell Histiocytosis (LCH) represents a rare benign disorder, previously designated as "Histiocytosis X", "Type II Histiocytosis" or "Langerhans Cell Granulomatosis". Clinical presentation includes osteolysis, ulcerations of skin and soft tissues but also involvement of the CNS is described.Because treatment concepts are not well defined the German Cooperative Group on Radiotherapy for Benign Diseases performed a retrospective analysis.
Methods and material: Eight closely cooperating centres collected patients' data of the past 45 years. As study endpoints disease free survival, recurrent disease, death and therapy related side effects were defined.
Results: A total of 80 patients with histologically proven LCH were irradiated within the past 45 years. According to the LCH classification of Greenberger et al. 37 patients had stage Ia, 21 patients stage Ib, 13 patients stage II and 9 patients stage IIIb and the median age was 29 years. The median Follow up was 54 months (range 9-134 months). A total of 39 patients had a surgical intervention and 23 patients a chemotherapy regimen.Radiation treatment was carried out with a median total dose of 15 Gy (range 3-50.4 Gy). The median single fraction was 2 Gy (range 1.8-3 Gy).Overall, 77% patients achieved a complete remission and 12.5% achieved a partial remission. The long-term control rate reached 80%. Within an actuarial overall 5-year survival of 90% no radiogenic side and late effects ≥EORTC/RTOG II° were observed.
Conclusion: In the present study a large collective of irradiated patients was analysed. Radiotherapy (RT) is a very effective and safe treatment option and even low RT doses show sufficient local control.
Background: A number of scientific papers on yellow fever have been published but no broad scientometric analysis on the published research of yellow fever has been reported. The aim of the article based study was to provide an in-depth evaluation of the yellow fever field using large-scale data analysis and employment of bibliometric indicators of production and quantity.
Methods: Data were retrieved from the Web of Science database (WoS) and analyzed as part of the NewQis platform. Then data were extracted from each file, transferred to databases and visualized as diagrams. Partially by means of density-equalizing mapping makes the findings clear and emphasizes the output of the analysis.
Results: In the study period from 1900 to 2012 a total of 5,053 yellow fever-associated items were published by 79 countries. The United States (USA) having the highest publication rate at 42% (n = 751) followed by far from Brazil (n = 203), France (n = 149) and the United Kingdom (n = 113). The most productive journals are the "Public Health Reports", the "American Journal of Tropical Medicine and Hygiene" and the "Journal of Virology". The gender analysis showed an overall steady increase of female authorship from 1950 to 2011. Brazil is the only country of the five most productive countries with a higher proportion of female scientists.
Conclusions: The present data shows an increase in research productivity over the entire study period, in particular an increase of female scientists. Brazil shows a majority of female authors, a fact that is confirmed by other studies.
Introduction: Postural control is a prerequisite to many everyday and sporting activities which requires the interaction of multiple sensorimotor processes. As long as we have no balance disorders, the maintenance of an erect standing position is taken for granted with automatic running control processes. It is well known that with increasing age or disease balance problems occur which often cause fall-related injuries. To assess balance performance, posturography is widely applied in which body sway is traditionally viewed as a manifestation of random fluctuations. Thus, the amount of sway is solely used as an index of postural stability, that is, less sway is an indication of better control. But, traditional measures of variability fail to account for the temporal organisation of postural sway. The concept of nonlinear dynamics suggests that variability in the motor output is not random but structured. It provides the stimulus to reveal the functionality of postural sway. This thesis evaluates nonlinear analysis tools in addition to classic linear methods in terms of age-related modifications of postural control and under different standing conditions in order to broaden the existing knowledge of postural control processes.
Methods: Static posturographic analyses were conducted which included the recording of centre of pressure (COP) time series by means of a force plate. Linear and nonlinear methods were used to quantify postural sway variability in order to evaluate both the amount and structure of sway. Classic time and frequency domain COP parameters were computed. In addition, wavelet transform (WT), multiscale entropy, detrended fluctuation analysis, and scaled windowed variance method were applied to COP signals in order to derive structural COP parameters. Two experiments were performed. 1) 16 young (26.1 ± 6.7 years), healthy subjects were asked to adopt a bipedal stance under single- and dual-task conditions. Three trials were conduced each with a different sampling duration: 30, 60, and 300 seconds [s]. 2) 26 young (28.15 ± 5.86 years) and 13 elderly (72 ± 7 years) subjects stood quietly for 60 s on five different surfaces which imposed different biomechanical constraints: level ground (LG), one foot on a step (ST), uphill (UH), downhill (DH), and slope (SL). Additional to COP recordings, limb load symmetry was assessed via foot pressure insoles.
Results: We found a higher sensitivity of structural COP parameters to modulations of postural control and partly an improved evaluation of sway dynamics in longer COP recordings. WT revealed a reweighing of frequency bands in response to altered standing conditions. Scaling exponents and entropy values of COP signals were task-dependent. Higher entropy values were found under the dual-task and condition ST. The time scales affected under the altered standing positions differed between groups and sway directions. Mainly larger posturograms were found in the elderly. Age effects were especially revealed in position ST and concerning medial-lateral COP signals. Load asymmetry was stronger in elderly subjects for LG, UH, and DH positions.
Discussion: Modifications of multiple time scales corresponds to an interplay of control subsystems to cope with the altered task demands. The affected time scales are age-dependent suggesting a change of control processes. Higher irregularity under the dual-task indicates a more complex motor output which is interpreted as less attentional investment into postural control. Larger complexity is evident for ST in contrast to LG position. ST obviously challenges lateral sway which is counteracted differently between groups. Load asymmetry suggests that especially elderly subjects adopt a step-initiation strategy.
Conclusion: A continued application of nonlinear methods is necessary to broaden the understanding of postural control mechanisms and to identify classifiers for balance dysfunctions. Structural COP parameters provide a more comprehensive indication of postural control system properties between groups and task demands. COP recordings of at least 60 s are recommended to adequately quantify COP signal structure. The analysis of postural strategies in everyday activities increases the ecological validity of postural control studies and can provide valuable information regarding the development of effective rehabilitation programs.
Vasoactive intestinal polypeptide (VIP) is a putative neurotransmitter of the inhibitory non-adrenergic non-cholinergic nervous system and influences the mammalian airway function in various ways. Hence known for bronchodilatory, immunomodulatory and mucus secretion modulating effects by interacting with the VIP receptors VPAC1 and VPAC2, it is discussed to be a promising target for pharmaceutical intervention in common diseases such as COPD and bronchial asthma. Here we examined the expression and transcriptional regulation of VPAC1 in the lungs of allergic mice using an ovalbumin (OVA) -induced model of allergic asthma. Mice were sensitized to OVA and challenged with an OVA aerosol. In parallel a control group was sham sensitized with saline. VPAC1 expression was examined using RT-PCR and real time-PCR studies were performed to quantify gene transcription. VPAC1 mRNA expression was detected in all samples of OVA-sensitized and challenged animals and control tissues. Further realtime analysis did not show significant differences at the transcriptional level.
Although the present studies did not indicate a major transcriptional regulation of VPAC1 in states of allergic airway inflammation, immunomodulatory effects of VPAC1 might still be present due to regulations at the translational level.
Purpose: Aberrant PI3K/AKT/mTOR signaling has been linked to oncogenesis and therapy resistance in various malignancies including leukemias. In Philadelphia chromosome (Ph) positive leukemias, activation of PI3K by dysregulated BCR-ABL tyrosine kinase (TK) contributes to the pathogenesis and development of resistance to ABL-TK inhibitors (TKI). The PI3K pathway thus is an attractive therapeutic target in BCR-ABL positive leukemias, but its role in BCR-ABL negative ALL is conjectural. Moreover, the functional contribution of individual components of the PI3K pathway in ALL has not been established.
Experimental design: We compared the activity of the ATP-competitive pan-PI3K inhibitor NVP-BKM120, the allosteric mTORC1 inhibitor RAD001, the ATP-competitive dual PI3K/mTORC1/C2 inhibitors NVP-BEZ235 and NVP-BGT226 and the combined mTORC1 and mTORC2 inhibitors Torin 1, PP242 and KU-0063794 using long-term cultures of ALL cells (ALL-LTC) from patients with B-precursor ALL that expressed the BCR-ABL or TEL-ABL oncoproteins or were BCR-ABL negative.
Results: Dual PI3K/mTOR inhibitors profoundly inhibited growth and survival of ALL cells irrespective of their genetic subtype and their responsiveness to ABL-TKI. Combined suppression of PI3K, mTORC1 and mTORC2 displayed greater antileukemic activity than selective inhibitors of PI3K, mTORC1 or mTORC1 and mTORC2.
Conclusions: Inhibition of the PI3K/mTOR pathway is a promising therapeutic approach in patients with ALL. Greater antileukemic activity of dual PI3K/mTORC1/C2 inhibitors appears to be due to the redundant function of PI3K and mTOR. Clinical trials examining dual PI3K/mTORC1/C2 inhibitors in patients with B-precursor ALL are warranted, and should not be restricted to particular genetic subtypes.
kurz und kn@pp news : Nr. 29
(2013)
Poster presentation: 28th Annual Scientific Meeting of the Society for Immunotherapy of Cancer (SITC)
Significant progress has been made over the last decade towards realizing the potential of natural killer (NK) cells for cancer immunotherapy. NK cells can respond rapidly to transformed and stressed cells, and have the intrinsic potential to extravasate and reach their targets in almost all body tissues. In addition to donor-derived primary NK cells, also continuously expanding cytotoxic cell lines such as NK-92 are being considered for adoptive cancer immunotherapy. High cytotoxicity of NK-92 has previously been shown against malignant cells of hematologic origin in preclinical studies, and general safety of infusion of NK-92 cells has been established in phase I clinical trials. To enhance their therapeutic utility, we genetically modified NK-92 cells to express chimeric antigen receptors (CAR) specific for tumor-associated surface antigens. Such CAR were composed of a tumor-specific scFv antibody fragment fused via hinge and transmembrane domains to intracellular signaling moieties such as CD3 zeta chain, or composite fusion molecules also containing a costimulatory protein domain in addition to CD3 zeta. For development towards clinical applications, here a codon-optimized second generation CAR was constructed that consists of an ErbB2-specific scFv antibody domain fused via a linker to a composite CD28-CD3 zeta signaling domain. GMP-compliant protocols for vector production, lentiviral transduction and expansion of a genetically modified NK-92 single cell clone (NK-92/5.28.z) were established. Functional analysis of NK-92/5.28.z cells revealed high and stable CAR expression, selective cytotoxicity against ErbB2-expressing but otherwise NK-resistant tumor cells of different origins in vitro, as well as homing to ErbB2-expressing tumors in vivo. Furthermore, antigen specificity and selective cytotoxicity of these cells were retained in vivo, resulting in antitumoral activity against subcutaneous and intracranial glioblastoma xenografts in NSG mice. Ongoing work now focuses on the development of these cells for adoptive immunotherapy of ErbB2-positive glioblastoma.
BACKGROUND: Systemic thrombolysis with recombinant tissue plasminogen activator (rt-PA) is the standard of acute stroke care. Its potential to increase the risk of secondary intracerebral hemorrhage, especially if administered late, has been ascribed to its proteolytic activity that has detrimental effects on blood-brain barrier (BBB) integrity after stroke. FTY720 has been shown to protect endothelial barriers in several disease models such as endotoxin-induced pulmonary edema and therefore is a promising candidate to counteract the deleterious effects of rt-PA. Besides that, every putative neuroprotectant that will be eventually forwarded into clinical trials should be tested in conjunction with rt-PA.
METHODS: We subjected C57Bl/6 mice to 3 h filament-induced tMCAO and postoperatively randomized them into four groups (n = 18/group) who received the following treatments directly prior to reperfusion: 1) vehicle-treatment, 2) FTY720 1 mg/kg i.p., 3) rt-PA 10 mg/kg i.v. or 4) FTY720 and rt-PA as a combination therapy. We measured functional neurological outcome, BBB disruption by quantification of EB extravasation and MMP-9 activity by gelatin zymography.
RESULTS: We observed a noticeable increase in mortality in the rt-PA/FTY720 cotreatment group (61%) as compared to the vehicle (33%), the FTY720 (39%) and the rt-PA group (44%). Overall, functional neurological outcome did not differ significantly between groups and FTY720 had no effect on rt-PA- and stroke-induced BBB disruption and MMP-9 activation.
CONCLUSIONS: Our data show that FTY720 does not improve functional outcome and BBB integrity in large hemispheric infarctions, neither alone nor in conjunction with rt-PA. These findings stand in contrast to a recently published study that showed beneficial effects of FTY720 in combination with thrombolysis in a thrombotic model of MCAO leading to circumscript cortical infarctions. They might therefore represent a caveat that the coadministration of these two drugs might lead to excess mortality in the setting of a severe stroke.
Early vascularization is a prerequisite for successful bone healing and endothelial progenitor cells (EPC), seeded on appropriate biomaterials, can improve vascularization. The type of biomaterial influences EPC function with bioglass evoking a vascularizing response. In this study the influence of a composite biomaterial based on polylactic acid (PLA) and either 20 or 40% bioglass, BG20 and BG40, respectively, on the differentiation and survival of EPCs in vitro was investigated. Subsequently, the effect of the composite material on early vascularization in a rat calvarial critical size defect model with or without EPCs was evaluated. Human EPCs were cultured with β-TCP, PLA, BG20 or BG40, and seeding efficacy, cell viability, cell morphology and apoptosis were analysed in vitro. BG40 released the most calcium, and improved endothelial differentiation and vitality best. This effect was mimicked by adding an equivalent amount of calcium to the medium and was diminished in the presence of the calcium chelator, EGTA. To analyze the effect of BG40 and EPCs in vivo, a 6-mm diameter critical size calvarial defect was created in rats (n = 12). Controls (n = 6) received BG40 and the treatment group (n = 6) received BG40 seeded with 5×105 rat EPCs. Vascularization after 1 week was significantly improved when EPCs were seeded onto BG40, compared to implanting BG40 alone. This indicates that Ca2+ release improves EPC differentiation and is useful for enhanced early vascularization in critical size bone defects.
B lymphocytes are an important cell population of the immune system. However, until recently it was not possible to transduce resting B lymphocytes with retro- or lentiviral vectors, making them unsusceptible for genetic manipulations by these vectors. Lately, we demonstrated that lentiviral vectors pseudotyped with modified measles virus (MV) glycoproteins hemagglutinin, responsible for receptor recognition, and fusion protein were able to overcome this transduction block. They use either the natural MV receptors, CD46 and signaling lymphocyte activation molecule (SLAM), for cell entry (MV-LV) or the vector particles were further modified to selectively enter via the CD20 molecule, which is exclusively expressed on B lymphocytes (CD20-LV). It has been shown previously that transduction by MV-LV does not induce B lymphocyte activation. However, if this is also true for CD20-LV is still unknown. Here, we generated a vector specific for another B lymphocyte marker, CD19, and compared its ability to transduce resting B lymphocytes with CD20-LV. The vector (CD19ds-LV) was able to stably transduce unstimulated B lymphocytes, albeit with a reduced efficiency of about 10% compared to CD20-LV, which transduced about 30% of the cells. Since CD20 as well as CD19 are closely linked to the B lymphocyte activation pathway, we investigated if engagement of CD20 or CD19 molecules by the vector particles induces activating stimuli in resting B lymphocytes. Although, activation of B lymphocytes often involves calcium influx, we did not detect elevated calcium levels. However, the activation marker CD71 was substantially up-regulated upon CD20-LV transduction and most importantly, B lymphocytes transduced with CD20-LV or CD19ds-LV entered the G1b phase of cell cycle, whereas untransduced or MV-LV transduced B lymphocytes remained in G0. Hence, CD20 and CD19 targeting vectors induce activating stimuli in resting B lymphocytes, which most likely renders them susceptible for lentiviral vector transduction.
In contrast to the commonly indolent clinical behavior of nodular lymphocyte predominant Hodgkin lymphoma (NLPHL), T cell/histiocyte rich large B cell lymphoma (THRLBCL) is frequently diagnosed in advanced clinical stages and has a poor prognosis. Besides the different clinical presentations of these lymphoma entities, there are variants of NLPHL with considerable histopathologic overlap compared to THRLBCL. Especially THRLBCL-like NLPHL, a diffuse form of NLPHL, often presents a histopathologic pattern similar to THRLBCL, suggesting a close relationship between both lymphoma entities. To corroborate this hypothesis, we performed gene expression profiling of microdissected tumor cells of NLPHL, THRLBCL-like NLPHL and THRLBCL. In unsupervised analyses, the lymphomas did not cluster according to their entity. Moreover, even in supervised analyses, very few consistently differentially expressed transcripts were found, and for these genes the extent of differential expression was only moderate. Hence, there are no clear and consistent differences in the gene expression of the tumor cells of NLPHL, THRLBCL-like NLPHL and THRLBCL. Based on the gene expression studies, we identified BAT3/BAG6, HIGD1A, and FAT10/UBD as immunohistochemical markers expressed in the tumor cells of all three lymphomas. Characterization of the tumor microenvironment for infiltrating T cells and histiocytes revealed significant differences in the cellular composition between typical NLPHL and THRLBCL cases. However, THRLBCL-like NLPHL presented a histopathologic pattern more related to THRLBCL than NLPHL. In conclusion, NLPHL and THRLBCL may represent a spectrum of the same disease. The different clinical behavior of these lymphomas may be strongly influenced by differences in the lymphoma microenvironment, possibly related to the immune status of the patient at the timepoint of diagnosis.
Visible light is a better co-inducer of apoptosis for curcumin-treated human melanoma cells than UVA
(2013)
Curcumin attracts worldwide scientific interest due to its anti-proliferative and apoptosis inducing effects on different tumor cells at concentrations ranging from 10 to 150 µM (3.7–55 µg/ml). Unfortunately, because of a low oral bioavailability, only low and pharmacologically ineffective serum levels are achievable. In this study, an alternative treatment concept consisting of low concentration curcumin (0.2–5 µg/ml) and irradiation with UVA or visible light (VL) has been tested. The experimental results show clearly that this treatment decreases the proliferation and the viability of human melanoma cells while the cell membrane integrity remains intact. We identified the onset of apoptosis characterized by typical markers such as active caspases 8, 9 and 3 as well as DNA fragmentation accompanied by the loss of cell adhesion. The mitochondrial apoptosis signaling pathway is predominant due to an early activation of caspase-9. The present data indicate a higher efficacy of a combination of curcumin and VL than curcumin and UVA. Reduced effects as a result of light absorption by heavily pigmented skin are unlikely if VL is used. These results indicate that a combination of curcumin and light irradiation may be a useful additional therapy in the treatment of malignant disease.
Hintergrund: Das Burkitt Lymphom und das Diffus großzellige B-Zell Lymphom können überlappende morphologische und immunhistochemische Eigenschaften aufweisen. Eine Differenzierung beider Entitäten ist klinisch relevant. Mit Hilfe von Genexpressionsanalysen an kryo-konservierten Proben hochmaligner B-Zell Lymphome, bestehend aus Burkitt Lymphomen und Diffus großzelligen B-Zell Lymphomen, gelang 2006 die molekulare Definition des Burkitt Lymphoms (mBL) mit einer burkittspezifischen Gensignatur (Genchip-Klassifikator). Demgegenüber wurden Proben, die nicht diese Signatur aufwiesen als non-mBL bezeichnet. Proben, die weder mBL noch non-mBL klassifiziert wurden, wurden als intermediär eingestuft.
Ziel: Entwicklung einer Methode zur Unterscheidung von mBL und non-mBL mittels quantitativer Echtzeit-Polymerase Kettenreaktion (qPCR) durch die Etablierung eines Assays-Sets einer kleinen Anzahl von Genen der mBL-Signatur an formalinfixiertem, in paraffineingebettetem (FFPE) Gewebe.
Methoden: An 116 Proben, bestehend aus mBL, non-mBL und intermediären Fällen (entsprechend der Genchip-Klassifikation) wurden qPCR Messungen für sechs Gene und ein Referenzgen durchgeführt. Die Expressionsmessungen wurden auf den vorhandenen Genchip-Klassifikator projiziert.
Ergebnisse: 90 von 116 Proben konnten mit dem qPCR-Klassifikator klassifiziert werden. Bei 22 Proben kam es zu Messausfällen. 4 Fälle wurden bioinformatisch ausgesondert.13 von 14 mBL, 59 von 61 non-mBL und 8 von15 intermediären Fällen wurden identisch zu dem Genchip-Klassifikator bewertet.
Diskussion: Der entwickelte qPCR-Klassifikator ist eine objektive, schnelle und kosteneffiziente diagnostische Herangehensweise zur Bestimmung des mBL. Nicht alle FFPE-Proben waren mit dem qPCR Klassifikator eindeutig auswertbar und für eine Klassifikation zu nutzen. Eine Einflussgröße hierbei stellt das Alter der Proben dar. Mit Hilfe dieser Untersuchung können retrospektive Analysen durchgeführt werden. Der Klassifikator kann zusätzlich zur Morphologie und Immunhistochemie mit eindeutiger Klassifikation von 93% (mBL) und 97% (non-mBL) angewendet werden.
Objective: To assess the prevalence of prenatal screening and of adverse outcome in high-risk pregnancies due to maternal HIV infection.
Study design: The prevalence of prenatal screening in 330 pregnancies of HIV-positive women attending the department for prenatal screening and/or during labour between January 1, 2002 and December 31, 2012, was recorded. Screening results were compared with the postnatal outcome and maternal morbidity, and mother-to-child transmission (MTCT) was evaluated.
Results: One hundred of 330 women (30.5%) had an early anomaly scan, 252 (74.5%) had a detailed scan at 20–22 weeks, 18 (5.5%) had a detailed scan prior to birth, and three (0.9%) had an amniocentesis. In seven cases (2.12%), a fetal anomaly was detected prenatally and confirmed postnatally, while in eight (2.42%) an anomaly was only detected postnatally, even though a prenatal scan was performed. There were no anomalies in the unscreened group. MTCT occurred in three cases (0.9%) and seven fetal and neonatal deaths (2.1%) were reported.
Conclusion: The overall prevalence of prenatal ultrasound screening in our cohort is 74.5%, but often the opportunity for prenatal ultrasonography in the first trimester is missed. In general, the aim should be to offer prenatal ultrasonography in the first trimester in all pregnancies. This allows early reassurance or if fetal disease is suspected, further steps can be taken.
Rho-family GTPases like RhoA and Rac-1 are potent regulators of cellular signaling that control gene expression, migration and inflammation. Activation of Rho-GTPases has been linked to podocyte dysfunction, a feature of chronic kidney diseases (CKD). We investigated the effect of Rac-1 and Rho kinase (ROCK) inhibition on progressive renal failure in mice and studied the underlying mechanisms in podocytes. SV129 mice were subjected to 5/6-nephrectomy which resulted in arterial hypertension and albuminuria. Subgroups of animals were treated with the Rac-1 inhibitor EHT1846, the ROCK inhibitor SAR407899 and the ACE inhibitor Ramipril. Only Ramipril reduced hypertension. In contrast, all inhibitors markedly attenuated albumin excretion as well as glomerular and tubulo-interstitial damage. The combination of SAR407899 and Ramipril was more effective in preventing albuminuria than Ramipril alone. To study the involved mechanisms, podocytes were cultured from SV129 mice and exposed to static stretch in the Flexcell device. This activated RhoA and Rac-1 and led via TGFβ to apoptosis and a switch of the cells into a more mesenchymal phenotype, as evident from loss of WT-1 and nephrin and induction of α-SMA and fibronectin expression. Rac-1 and ROCK inhibition as well as blockade of TGFβ dramatically attenuated all these responses. This suggests that Rac-1 and RhoA are mediators of podocyte dysfunction in CKD. Inhibition of Rho-GTPases may be a novel approach for the treatment of CKD.
Paraneoplastic cerebellar degeneration associated with lymphoepithelial carcinoma of the tonsil
(2013)
Background: Paraneoplastic cerebellar degeneration (PCD) is a classical tumor-associated, immune-mediated disease typically associated with gynecological malignancies, small-cell lung-cancer or lymphoma.
Case presentation: Here we present the case of a 38-year old male with an over 12 months rapidly progressive cerebellar syndrome. Extensive diagnostic workup revealed selective hypermetabolism of the right tonsil in whole-body PET. Histological examination after tonsillectomy demonstrated a lymphoepithelial carcinoma of the tonsil and the tongue base strongly suggesting a paraneoplastic cause of the cerebellar syndrome. To the best of our knowledge this is the first case of an association of a lymphoepithelial carcinoma, a rare pharyngeal tumor, with PCD.
Conclusions: In cases of classical paraneoplastic syndromes an extensive search for neoplasms should be performed including whole-body PET to detect tumors early in the course of the disease.
Background: Tobacco is a leading environmental factor in the initiation of respiratory diseases and causes chronic obstructive pulmonary disease (COPD). Suppressor of cytokine signaling (SOCS) family members are involved in the pathogenesis of many inflammatory diseases and SOCS-3 has been shown to play an important role in the regulation, onset and maintenance of airway allergic inflammation indicating that SOCS-3 displays a potential therapeutic target for anti-inflammatory respiratory drugs development. Since chronic obstructive pulmonary disease (COPD) is also characterized by inflammatory changes and airflow limitation, the present study assessed the transcriptional expression of SOCS-3 in COPD.
Methods: Real-time PCR was performed to assess quantitative changes in bronchial biopsies of COPD patients in comparison to unaffected controls.
Results: SOCS-3 was significantly down-regulated in COPD at the transcriptional level while SOCS-4 and SOCS-5 displayed no change.
Conclusions: It can be concluded that the presently observed inhibition of SOCS-3 mRNA expression may be related to the dysbalance of cytokine signaling observed in COPD.
The concept of focal epilepsies includes a seizure origin in brain regions with hyper synchronous activity (epileptogenic zone and seizure onset zone) and a complex epileptic network of different brain areas involved in the generation, propagation, and modulation of seizures. The purpose of this work was to study functional and effective connectivity between regions involved in networks of epileptic seizures. The beginning and middle part of focal seizures from ictal surface EEG data were analyzed using dynamic imaging of coherent sources (DICS), an inverse solution in the frequency domain which describes neuronal networks and coherences of oscillatory brain activities. The information flow (effective connectivity) between coherent sources was investigated using the renormalized partial directed coherence (RPDC) method. In 8/11 patients, the first and second source of epileptic activity as found by DICS were concordant with the operative resection site; these patients became seizure free after epilepsy surgery. In the remaining 3 patients, the results of DICS / RPDC calculations and the resection site were discordant; these patients had a poorer post-operative outcome. The first sources as found by DICS were located predominantly in cortical structures; subsequent sources included some subcortical structures: thalamus, Nucl. Subthalamicus and cerebellum. DICS seems to be a powerful tool to define the seizure onset zone and the epileptic networks involved. Seizure generation seems to be related to the propagation of epileptic activity from the primary source in the seizure onset zone, and maintenance of seizures is attributed to the perpetuation of epileptic activity between nodes in the epileptic network. Despite of these promising results, this proof of principle study needs further confirmation prior to the use of the described methods in the clinical praxis.
Background & Aims: Genetic variations near the interferon lambda 3 gene (IFNL3, IL28B) are the most powerful predictors for sustained virologic response (SVR) in patients with chronic hepatitis C virus (HCV) infection, compared to other biochemical or histological baseline parameters. We evaluated whether the interplay of both IFNL3 polymorphisms rs12979860 and rs8099917 together with non-genetic clinical factors contributes to the predictive role of these genetic variants.
Methods: The cohort comprised 1,402 patients of European descent with chronic HCV type 1 infection. 1,298 patients received interferon-based antiviral therapy, and 719 (55%) achieved SVR. The IFNL3 polymorphisms were genotyped by polymerase chain reaction and melting curve analysis.
Results: A significant correlation was found between the IFNL3 polymorphisms and biochemical as well as virologic predictors of treatment outcome such as ALT, GGT, cholesterol, and HCV RNA levels. In multivariate regression analysis, IFLN3 SNPs, HCV RNA levels, and the GGT/ALT ratio were independent predictors of SVR. Dependent on the GGT/ALT ratio and on the HCV RNA concentration, significant variations in the likelihood for achieving SVR were observed in both, carriers of the responder as well as non-responder alleles.
Conclusions: Our data support a clear association between IFNL3 genotypes and baseline parameters known to impact interferon responsiveness. Improved treatment outcome prediction was achieved when these predictors were considered in combination with the IFNL3 genotype.
Background: Thyroid Imaging Reporting and Data System (TIRADS) was developed to improve patient management and cost-effectiveness by avoiding unnecessary fine needle aspiration biopsy (FNAB) in patients with thyroid nodules. However, its clinical use is still very limited. Strain elastography (SE) enables the determination of tissue elasticity and has shown promising results for the differentiation of thyroid nodules.
Methods: The aim of the present study was to evaluate the interobserver agreement (IA) of TIRADS developed by Horvath et al. and SE. Three blinded observers independently scored stored images of TIRADS and SE in 114 thyroid nodules (114 patients). Cytology and/or histology was available for all benign (n = 99) and histology for all malignant nodules (n = 15).
Results: The IA between the 3 observers was only fair for TIRADS categories 2–5 (Coheńs kappa = 0.27,p = 0.000001) and TIRADS categories 2/3 versus 4/5 (ck = 0.25,p = 0.0020). The IA was substantial for SE scores 1–4 (ck = 0.66,p<0.000001) and very good for SE scores 1/2 versus 3/4 (ck = 0.81,p<0.000001). 92–100% of patients with TIRADS-2 had benign lesions, while 28–42% with TIRADS-5 had malignant cytology/histology. The negative-predictive-value (NPV) was 92–100% for TIRADS using TIRADS-categories 4&5 and 96–98% for SE using score ES-3&4 for the diagnosis of malignancy, respectively. However, only 11–42% of nodules were in TIRADS-categories 2&3, as compared to 58–60% with ES-1&2.
Conclusions: IA of TIRADS developed by Horvath et al. is only fair. TIRADS and SE have high NPV for excluding malignancy in the diagnostic work-up of thyroid nodules.
Wassergefiltertes Infrarot A (wIRA) bezeichnet eine spezielle Form der Infrarotstrahlung (Wärmestrahlung) im Bereich von 780 bis 1.400 nm, die aufgrund ihrer sehr guten Verträglichkeit in der Medizin zur Prävention und Therapie verwendet wird. wIRA steigert Temperatur, Sauerstoffpartialdruck und Durchblutung im Gewebe. Wesentliche klinische Wirkungen von wIRA sind – indikationsübergreifend – eine ausgeprägte Minderung von Schmerzen, Entzündung und vermehrter Flüssigkeitsabgabe sowie eine Verbesserung der Infektabwehr und der Regeneration.
Plus Puls : 2013, 4
(2013)
Plus Puls : 2013, 3
(2013)
Plus Puls : 2013, 2
(2013)
Plus Puls : 2013, 1
(2013)
Aim: To evaluate the effectiveness of two different strategies using radiofrequency catheter ablation for redo procedures after cryoablation of atrial fibrillation.
Methods: Thirty patients (paroxysmal atrial fibrillation: 22 patients, persistent atrial fibrillation: 8 patients) had to undergo a redo procedure after initially successful circumferential pulmonary vein (PV) isolation with the cryoballoon technique (Arctic Front Balloon, CryoCath Technologies/Medtronic). The redo ablation procedures were performed using a segmental approach or a circumferential ablation strategy (CARTO; Biosense Webster) depending on the intra-procedural findings. After discharge, patients were scheduled for repeated visits at the arrhythmia clinic. A 7-day Holter monitoring was performed at 3, 12 and 24 mo after the ablation procedure.
Results: During the redo procedure, a mean number of 2.9 re-conducting pulmonary veins (SD ± 1.0 PVs) were detected (using a circular mapping catheter). In 20 patients, a segmental approach was sufficient to eliminate the residual pulmonary vein conduction because there were only a few recovered pulmonary vein fibres. In the remaining 10 patients, a circumferential ablation strategy was used because of a complete recovery of the PV-LA conduction. All recovered pulmonary veins could be isolated successfully again. At 2-year follow-up, 73.3% of all patients were free from an arrhythmia recurrence (22/30). There were no major complications.
Conclusion: In patients with an initial circumferential pulmonary vein isolation using the cryoballoon technique, a repeat ablation procedure can be performed safely and effectively using radiofrequency catheter ablation.
Background: Standard treatment for venous thromboembolism (VTE) consists of a heparin combined with vitamin K antagonists. Direct oral anticoagulants have been investigated for acute and extended treatment of symptomatic VTE; their use could avoid parenteral treatment and/or laboratory monitoring of anticoagulant effects.
Methods: A prespecified pooled analysis of the EINSTEIN-DVT and EINSTEIN-PE studies compared the efficacy and safety of rivaroxaban (15 mg twice-daily for 21 days, followed by 20 mg once-daily) with standard-therapy (enoxaparin 1.0 mg/kg twice-daily and warfarin or acenocoumarol). Patients were treated for 3, 6, or 12 months and followed for suspected recurrent VTE and bleeding. The prespecified noninferiority margin was 1.75.
Results: 8282 patients were enrolled. 4151 received rivaroxaban and 4131 received standard-therapy. The primary efficacy outcome occurred in 86 rivaroxaban-treated patients (2.1%) compared with 95 (2.3%) standard-therapy-treated patients (hazard ratio, 0.89; 95% confidence interval [CI], 0.66-1.19; pnoninferiority<0.001). Major bleeding was observed in 40 (1.0%) and 72 (1.7%) patients in the rivaroxaban and standard-therapy groups, respectively (hazard ratio, 0.54; 95% CI, 0.37-0.79; p=0.002). In key subgroups, including fragile patients, cancer patients, patients presenting with large clots and those with a history of recurrent VTE, the efficacy and safety of rivaroxaban was similar compared with standard-therapy.
Conclusion: The single-drug approach with rivaroxaban resulted in similar efficacy to standard-therapy and was associated with a significantly lower rate of major bleeding. Efficacy and safety results were consistent among key patient subgroups.
Aim: To compare clinical success and complications of uncovered self-expanding metal stents (SEMS) vs covered SEMS (cSEMS) in obstruction of the small bowel.
Methods: Technical success, complications and outcome of endoscopic SEMS or cSEMS placement in tumor related obstruction of the duodenum or jejunum were retrospectively assessed. The primary end points were rates of stent migration and overgrowth. Secondary end points were the effect of concomitant biliary drainage on migration rate and overall survival. The data was analyzed according to the Strengthening the Reporting of Observational Studies in Epidemiology guidelines.
Results: Thirty-two SEMS were implanted in 20 patients. In all patients, endoscopic stent implantation was successful. Stent migration was observed in 9 of 16 cSEMS (56%) in comparison to 0/16 SEMS (0%) implantations (P = 0.002). Stent overgrowth did not significantly differ between the two stent types (SEMS: 3/16, 19%; cSEMS: 2/16, 13%). One cSEMS dislodged and had to be recovered from the jejunum by way of laparotomy. Time until migration between SEMS and cSEMS in patients with and without concomitant biliary stents did not significantly differ (HR = 1.530, 95%CI 0.731-6.306; P = 0.556). The mean follow-up was 57 ± 71 d (range: 1-275 d).
Conclusion: SEMS and cSEMS placement is safe in small bowel tumor obstruction. However, cSEMS is accompanied with a high rate of migration in comparison to uncovered SEMS.
Background: Novel influenza in 2009 caused by H1N1, as well as the seasonal influenza, still are a challenge for the public health sectors worldwide. An increasing number of publications referring to this infectious disease make it difficult to distinguish relevant research output. The current study used scientometric indices for a detailed investigation on influenza related research activity and the method of density equalizing mapping to make the differences of the overall research worldwide obvious. The aim of the study was to compare scientific effort over the time as well as geographical distribution including the cooperation on national and international level.
Methods: Therefore, publication data was retrieved from Web of Science (WoS) of Thomson Scientific. Subsequently the data was analysed in order to show geographical distributions and the development of the research output over the time.
The query retrieved 51,418 publications that are listed in WoS for the time interval from 1900 to 2009. There is a continuous increase in research output and general citation activity especially since 1990.
Results: The identified all in all 51,418 publications were published by researchers from 151 different countries. Scientists from the USA participate in more than 37 percent of all publications, followed by researchers from the UK and Germany with more than five percent. In addition, the USA is in the focus of international cooperation.
In terms of number of publications on influenza, the Journal of Virology ranks first, followed by Vaccine and Virology. The highest impact factor (IF 2009) in this selection can be established for The Lancet (30.75). Robert Webster seems to be the most prolific author contributing the most publications in the field of influenza.
Conclusions: This study reveals an increasing and wide research interest in influenza. Nevertheless, citation based-declaration of scientific quality should be considered critically due to distortion by self-citation and co-authorship.
Background: The brain cancer stem cell (CSC) model describes a small subset of glioma cells as being responsible for tumor initiation, conferring therapy resistance and tumor recurrence. In brain CSC, the PI3-K/AKT and the RAS/mitogen activated protein kinase (MAPK) pathways are found to be activated. In consequence, the human transcription factor YB-1, knowing to be responsible for the emergence of drug resistance and driving adenoviral replication, is phosphorylated and activated. With this knowledge, YB-1 was established in the past as a biomarker for disease progression and prognosis. This study determines the expression of YB-1 in glioblastoma (GBM) specimen in vivo and in brain CSC lines. In addition, the capacity of Ad-Delo3-RGD, an YB-1 dependent oncolytic adenovirus, to eradicate CSC was evaluated both in vitro and in vivo.
Methods: YB-1 expression was investigated by immunoblot and immuno-histochemistry. In vitro, viral replication as well as the capacity of Ad-Delo3-RGD to replicate in and, in consequence, to kill CSC was determined by real-time PCR and clonogenic dilution assays. In vivo, Ad-Delo3-RGD-mediated tumor growth inhibition was evaluated in an orthotopic mouse GBM model. Safety and specificity of Ad-Delo3-RGD were investigated in immortalized human astrocytes and by siRNA-mediated downregulation of YB-1.
Results: YB-1 is highly expressed in brain CSC lines and in GBM specimen. Efficient viral replication in and virus-mediated lysis of CSC was observed in vitro. Experiments addressing safety aspects of Ad-Delo3-RGD showed that (i) virus production in human astrocytes was significantly reduced compared to wild type adenovirus (Ad-WT) and (ii) knockdown of YB-1 significantly reduced virus replication. Mice harboring othotopic GBM developed from a temozolomide (TMZ)-resistant GBM derived CSC line which was intratumorally injected with Ad-Delo3-RGD survived significantly longer than mice receiving PBS-injections or TMZ treatment.
Conclusion: The results of this study supported YB-1 based virotherapy as an attractive therapeutic strategy for GBM treatment which will be exploited further in multimodal treatment concepts.
Die Transkription ist ein entscheidender Schritt in der Transition der genetischen Information, welche durch die DNA codiert und im Genom hinterlegt ist, zu dreidimensionalen Funktionseinheiten in der Zelle, den Proteinen. Während der Transkription wird die Information von der Ebene der DNA in RNA umgewandelt, welche in der Zelle zusätzlich zu dessen Rolle als Informationsmediator in Form der mRNA eine Vielzahl von Funktionen ausübt. Die Transkription benötigt in Hinblick auf ihre essentielle Rolle in der Errichtung des Proteoms und der notwendigen Adaption von Genexpressionsprogrammen an externe zelluläre Stimuli, den Zellzyklus etc. eine präzise und gleichzeitig flexible Regulation. Besonders für die Transkription von mRNA dient die eukaryotische RNA-Polymerase II (RNAP II) in diesem Prozess als eine zentrale Einheit, die einer Vielzahl regulativer Mechanismen wie post-translationaler Modifikationen und der Assemblierung dynamischer Proteinkomplexe unterliegt. Während Komponenten dieser Regulation wie die Zusammensetzung und Dynamik des Prä-Initiationskomplex bereits seit Jahrzehnten beschrieben sind, ist eine besondere Form der RNAP II-abhängigen Regulation erst in den letzten Jahren Gegenstand genauerer Untersuchungen geworden. So erfährt die RNAP II bei einer Vielzahl von Genen unmittelbar nach der Initiation einen Arrest, der das Enzym nicht weiter über die DNA prozessieren lässt und somit die produktive Elongation des Gens blockiert. Die Aufhebung dieser Blockade wird durch den positiven Transkriptions-elongationsfaktor b (P-TEFb) dominiert, der durch distinkte post-translationale Modifikationen der C-terminalen Domäne der RNAP II und assoziierter Faktoren die produktive Elongation ermöglicht. P-TEFb selbst unterliegt dabei einer strengen Regulation durch eine inaktivierende Assoziation mit Speicherkomplexen. P-TEFb wurde abseits dieser Komplexe in einer Vielzahl von Elongations-assoziierten Proteinkomplexen identifiziert, der Mechanismus der Transition aus dem inaktiven Speicherkomplex zur aktiven Form an der RNAP II war jedoch unbekannt.
Ein zentrales Element aller aktiven Komplexe ist die Anwesenheit von Proteinen der AF4/FMR2-Familie, darunter das AF4 Protein. Bemerkenswerterweise war die genaue Rolle dieses Proteins in den Komplexen bisher unbekannt oder wurde lediglich auf die strukturelle Integrität der Komplexe beschränkt. AF4 und speziell dessen N-Terminus ist über diese Rolle hinaus als Bestandteil des Fusionsproteins AF4-MLL eng mit der onkogenen Zelltransformation im Falle einer durch die t(4;11)(q21;q23) chromosomalen Translokation bedingter, akuter lymphoblastischer Leukämie assoziiert.
In dieser Arbeit konnte gezeigt werden, dass das AF4 Protein und im Speziellen sein N-Terminus in der Lage ist, die zelluläre Transkription durch die Aktivierung und Rekrutierung von P-TEFb zu aktivieren. In Anwesenheit von AF4 wird die Kinase-Untereinheit CDK9 des P-TEFb post-translational an Lysinresten modifiziert und damit aktiviert sowie die C-terminale Domäne der RNAP II im Kontext stärker phosphoryliert. Gleichzeitig wurde das P-TEFb inaktivierende Protein HEXIM1 stärker exprimiert. AF4 und AF4-MLL waren weiterhin in der Lage ein Elongations-kontrolliertes Reportergen zu aktivieren. Gleichzeitig führte die Überexpression des AF4 zu einer Erhöhung der zellulären RNA Menge. Zur genaueren Untersuchung der AF4-abhängigen Mechanismen wurden zwei Zelllinien erstellt, die zum Einen eine induzierbare und reproduzierbare Überexpression und Reinigung des AF4 erlaubten (TCZP-AF4ST) und zum Anderen durch lentiviralen knock-down eine an AF4-Mangelsituation nachstellten (AF4kd V100). Es konnte so gezeigt werden, dass AF4 über P-TEFb hinaus eine regulative Funktion gegenüber Transkription-assoziierten Faktoren wie CDK7, MENIN und NF?B besitzt und dass diese Faktoren vorrangig, analog zu P-TEFb, mit dem N-Terminus des AF4 interagieren. Die Überexpression von AF4 führte über die Bindung an die 7SK snRNA und deren Degradation zur Rekrutierung des P-TEFb aus den Speicherkomplexen in distinkte AF4-assoziierte Komplexe und zu einer Umverteilung des Faktors auf distinkte Loci im Zellkern, wobei der AF4 N-Terminus für sich alleine jedoch nicht in der Lage war, diese Funktion auszuüben. Im Falle eines Mangels an AF4 kam es zur Wachstumsretardierung der Zellen sowie zu einem völligen Aktivitätsverlust in Reportergenversuchen.
Die Tatsache, dass AF4 ein zentrales Element in der Elongationskontrolle darstellt führte zu der weitergehenden Vermutung, dass virale immediate early (IE) Proteine zur Kontrolle viraler Genexpression auf der Ebene der Elongation ebenfalls auf dieses Wirtsprotein zugreifen können. Es konnte vor diesem Hintergrund gezeigt werden, dass AF4 tatsächlich mit den IE-Proteinen IE1 (HCMV) und Zta (EBV) aus der Familie der Herpesviren interagiert und durch die Stabilisierung des AF4 Proteins eine kooperative, transaktivierende Funktion auf ein ALOX5 Reportergen ausgeübt wurde. Es wurde gezeigt, dass die viralen IE-Proteine dabei Komponenten der AF4 Komplexe sind und in der Zelle zur epigenetischen Regulation des ALOX5 Gens führen. Weiterhin konnte in diesen Experimenten dargestellt werden, dass AF4 über seine Rolle in der Elongationskontrolle hinaus auch distinkte Effekte in der Aktivierung von Promotoren und damit in der Initiation der Transkription zeigt. Damit konnte in dieser Arbeit zum ersten Mal die essentielle Rolle des AF4 Proteins in der Elongationskontrolle und der Initiation der Transkription als auch in der Infektion durch Herpesviren gezeigt werden.
Insertion of bone substitution materials accelerates healing of osteoporotic fractures. Biodegradable materials are preferred for application in osteoporotic patients to avoid a second surgery for implant replacement. Degraded implant fragments are often absorbed by macrophages that are removed from the fracture side via passage through veins or lymphatic vessels. We investigated if lymphatic vessels occur in osteoporotic bone defects and whether they are regulated by the use of different materials. To address this issue osteoporosis was induced in rats using the classical method of bilateral ovariectomy and additional calcium and vitamin deficient diet. In addition, wedge-shaped defects of 3, 4, or 5 mm were generated in the distal metaphyseal area of femur via osteotomy. The 4 mm defects were subsequently used for implantation studies where bone substitution materials of calcium phosphate cement, composites of collagen and silica, and iron foams with interconnecting pores were inserted. Different materials were partly additionally functionalized by strontium or bisphosphonate whose positive effects in osteoporosis treatment are well known. The lymphatic vessels were identified by immunohistochemistry using an antibody against podoplanin. Podoplanin immunopositive lymphatic vessels were detected in the granulation tissue filling the fracture gap, surrounding the implant and growing into the iron foam through its interconnected pores. Significant more lymphatic capillaries were counted at the implant interface of composite, strontium and bisphosphonate functionalized iron foam. A significant increase was also observed in the number of lymphatics situated in the pores of strontium coated iron foam. In conclusion, our results indicate the occurrence of lymphatic vessels in osteoporotic bone. Our results show that lymphatic vessels are localized at the implant interface and in the fracture gap where they might be involved in the removal of lymphocytes, macrophages, debris and the implants degradation products. Therefore the lymphatic vessels are involved in implant integration and fracture healing.
Neuronal ceroid lipofuscinosis (NCL) is a group of neurodegenerative lysosomal storage disorders characterized by vision loss, mental and motor deficits, and spontaneous seizures. Neuropathological analyses of autopsy material from NCL patients and animal models revealed brain atrophy closely associated with glial activity. Earlier reports also noticed loss of retinal cells and reactive gliosis in some forms of NCL. To study this phenomenon in detail, we analyzed the ocular phenotype of CLN6nclf mice, an established mouse model for variant-late infantile NCL. Retinal morphometry, immunohistochemistry, optokinetic tracking, electroretinography, and mRNA expression were used to characterize retinal morphology and function as well as the responses of Müller cells and microglia. Our histological data showed a severe and progressive degeneration in the CLN6nclf retina co-inciding with reactive Müller glia. Furthermore, a prominent phenotypic transformation of ramified microglia to phagocytic, bloated, and mislocalized microglial cells was identified in CLN6nclf retinas. These events overlapped with a rapid loss of visual perception and retinal function. Based on the strong microglia reactivity we hypothesized that dietary supplementation with immuno-regulatory compounds, curcumin and docosahexaenoic acid (DHA), could ameliorate microgliosis and reduce retinal degeneration. Our analyses showed that treatment of three-week-old CLN6nclf mice with either 5% DHA or 0.6% curcumin for 30 weeks resulted in a reduced number of amoeboid reactive microglia and partially improved retinal function. DHA-treatment also improved the morphology of CLN6nclf retinas with a preserved thickness of the photoreceptor layer in most regions of the retina. Our results suggest that microglial reactivity closely accompanies disease progression in the CLN6nclf retina and both processes can be attenuated with dietary supplemented immuno-modulating compounds.
Background: Hereditary angioedema (HAE), caused by deficiency in C1-inhibitor (C1-INH), leads to unpredictable edema of subcutaneous tissues with potentially fatal complications. As surgery can be a trigger for edema episodes, current guidelines recommend preoperative prophylaxis with C1-INH or attenuated androgens in patients with HAE undergoing surgery. However, the risk of an HAE attack in patients without prophylaxis has not been quantified.
Objectives: This analysis examined rates of perioperative edema in patients with HAE not receiving prophylaxis.
Methods: This was a retrospective analysis of records of randomly selected patients with HAE type I or II treated at the Frankfurt Comprehensive Care Centre. These were examined for information about surgical procedures and the presence of perioperative angioedema.
Results: A total of 331 patients were included; 247 underwent 700 invasive procedures. Of these procedures, 335 were conducted in 144 patients who had not received prophylaxis at the time of surgery. Categories representing significant numbers of procedures were abdominal (n = 113), ENT (n = 71), and gynecological (n = 58) procedures. The rate of documented angioedema without prophylaxis across all procedures was 5.7%; in 24.8% of procedures, the presence of perioperative angioedema could not be excluded, leading to a maximum potential risk of 30.5%. Predictors of perioperative angioedema could not be identified.
Conclusion: The risk of perioperative angioedema in patients with HAE type I or II without prophylaxis undergoing surgical procedures ranged from 5.7% to 30.5% (CI 3.5–35.7%). The unpredictability of HAE episodes supports current international treatment recommendations to consider short-term prophylaxis for all HAE patients undergoing surgery.
Mobilized blood has supplanted bone marrow (BM) as the primary source of hematopoietic stem cells for autologous and allogeneic stem cell transplantation. Pharmacologically enforced egress of hematopoietic stem cells from BM, or mobilization, has been achieved by directly or indirectly targeting the CXCL12/CXCR4 axis. Shortcomings of the standard mobilizing agent, granulocyte colony-stimulating factor (G-CSF), administered alone or in combination with the only approved CXCR4 antagonist, Plerixafor, continue to fuel the quest for new mobilizing agents. Using Protein Epitope Mimetics technology, a novel peptidic CXCR4 antagonist, POL5551, was developed. In vitro data presented herein indicate high affinity to and specificity for CXCR4. POL5551 exhibited rapid mobilization kinetics and unprecedented efficiency in C57BL/6 mice, exceeding that of Plerixafor and at higher doses also of G-CSF. POL5551-mobilized stem cells demonstrated adequate transplantation properties. In contrast to G-CSF, POL5551 did not induce major morphological changes in the BM of mice. Moreover, we provide evidence of direct POL5551 binding to hematopoietic stem and progenitor cells (HSPCs) in vivo, strengthening the hypothesis that CXCR4 antagonists mediate mobilization by direct targeting of HSPCs. In summary, POL5551 is a potent mobilizing agent for HSPCs in mice with promising therapeutic potential if these data can be orroborated in humans.
The role of the mRNA-binding protein human antigen R (HuR) in stabilization and translation of AU-rich elements (ARE) containing mRNAs is well established. However, the trafficking of HuR and bound mRNA cargo, which comprises a fundamental requirement for the aforementioned HuR functions is only poorly understood. By administering different cytoskeletal inhibitors, we found that the protein kinase Cδ (PKCδ)-triggered accumulation of cytoplasmic HuR by Angiotensin II (AngII) is an actin-myosin driven process functionally relevant for stabilization of ARE-bearing mRNAs. Furthermore, we show that the AngII-induced recruitment of HuR and its bound mRNA from ribonucleoprotein particles to free and cytoskeleton bound polysomes strongly depended on an intact actomyosin cytoskeleton. In addition, HuR allocation to free and cytoskeletal bound polysomes is highly sensitive toward RNase and PPtase and structurally depends on serine 318 (S318) located within the C-terminal RNA recognition motif (RRM3). Conversely, the trafficking of the phosphomimetic HuRS318D, mimicking HuR phosphorylation at S318 by the PKCδ remained PPtase resistant. Co-immunoprecipitation experiments with truncated HuR proteins revealed that the stimulus-induced association of HuR with myosin IIA is strictly RNA dependent and mediated via the RRM3. Our data implicate a microfilament dependent transport of HuR, which is relevant for stimulus-induced targeting of ARE-bearing mRNAs from translational inactive ribonucleoprotein particles to polysomes.
Background: Patients suffering from acute type A aortic dissection undergo replacement of the ascending aorta, the proximal hemiarch or complete aortic arch, depending on the extent of the individual pathology. In a subset of these treated patients, secondary pathologies of the distal anastomosis or the remaining distal part of the aorta occur. The treatment of these pathologies is challenging, requiring major surgical re-do procedures with aortic arch replacement under extracorporeal circulation and hypothermic circulatory arrest.
Methods: We report our experience of five patients with complex aortic pathologies after previous aortic surgery treated with a single stage re-do hybrid procedure, consisting of bypass grafting of the supraaortic branches off-pump, stent graft placement for endovascular aortic repair (TEVAR) and surgical debranching of the aortic arch.
Results: In all patients the surgical vascular grafts and stent grafts were deployed successfully, there were no intraoperative deaths. Four out of five patients were discharged from hospital in good clinical condition. One patient died postoperatively due to cardiac tamponade. In one patient a type I endoleak persisted leading to occlusion of a bypass branch requiring surgical revision at one year after debranching.
Conclusion: We discuss the prerequisites, all steps and potential pitfalls of this hybrid aortic arch replacement. The current procedure avoids cardiopulmonary bypass and circulatory arrest, which may benefit early patient outcome; however, patient and device selection plays a key role for immediate success and midterm outcomes. In addition, precise procedural planning and development of customized stents may help to develop this procedure into a true alternative for conventional aortic arch replacement.
BACKGROUND: The AGO-ETC trial compared 5-year relapse-free survival of intense dose-dense (IDD) sequential chemotherapy with epirubicin (E), paclitaxel (T), and cyclophosphamide (C) (IDD-ETC) every 2 weeks vs conventional scheduled epirubicin/cyclophosphamide followed by paclitaxel (EC→T) (every 3 weeks) as adjuvant treatment in high-risk breast cancer patients. The objective of this study was to evaluate the safety and efficacy of epoetin alfa in a second randomization of the intense dose-dense arm.
METHODS: One thousand two hundred eighty-four patients were enrolled; 658 patients were randomly assigned to the IDD-ETC treatment group. Within the IDD-ETC group, 324 patients were further randomly assigned to the epoetin alfa group, and 319 were randomly assigned to the non-erythropoiesis-stimulating agent (ESA) control group. Primary efficacy endpoints included change in hemoglobin level from baseline to Cycle 9 and the percentage of subjects requiring red blood cell transfusion. Relapse-free survival, overall survival, and intramammary relapse were secondary endpoints estimated with Kaplan-Meier and Cox regression methods. Except for the primary hypothesis, all statistical tests were two-sided.
RESULTS: Epoetin alfa avoided the decrease in hemoglobin level (no decrease in the epoetin alfa group vs -2.20g/dL change for the control group; P < .001) and statistically significantly reduced the percentage of subjects requiring red blood cell transfusion (12.8% vs 28.1%; P < .0001). The incidence of thrombotic events was 7% in the epoetin alfa arm vs 3% in the control arm. After a median follow-up of 62 months, epoetin alfa treatment did not affect overall survival, relapse-free survival, or intramammary relapse.
CONCLUSIONS: Epoetin alfa resulted in improved hemoglobin levels and decreased transfusions without an impact on relapse-free or overall survival. However, epoetin alfa had an adverse effect, resulting in increased thrombosis.
BACKGROUND: To report the clinical outcome of high dose rate brachytherapy as sole treatment for clinically localised prostate cancer.
METHODS: Between March 2004 and January 2008, a total of 351 consecutive patients with clinically localised prostate cancer were treated with transrectal ultrasound guided high dose rate brachytherapy. The prescribed dose was 38.0 Gy in four fractions (two implants of two fractions each of 9.5 Gy with an interval of 14 days between the implants) delivered to an intraoperative transrectal ultrasound real-time defined planning treatment volume. Biochemical failure was defined according to the Phoenix Consensus and toxicity evaluated using the Common Toxicity Criteria for Adverse Events version 3.
RESULTS: The median follow-up time was 59.3 months. The 36 and 60 month biochemical control and metastasis-free survival rates were respectively 98%, 94% and 99%, 98%. Toxicity was scored per event with 4.8% acute Grade 3 genitourinary and no acute Grade 3 gastrointestinal toxicity. Late Grade 3 genitourinary and gastrointestinal toxicity were respectively 3.4% and 1.4%. No instances of Grade 4 or greater acute or late adverse events were reported.
CONCLUSIONS: Our results confirm high dose rate brachytherapy as safe and effective monotherapy for clinically organ-confined prostate cancer.
Potential abnormalities in the structure and function of the temporal lobes have been studied much less in bipolar disorder than in schizophrenia. This may not be justified because language-related symptoms, such as pressured speech and flight of ideas, and cognitive deficits in the domain of verbal memory are amongst the hallmark of bipolar disorder (BD), and contribution of temporal lobe dysfunction is therefore likely. In the current study, we examined resting-state functional connectivity (FC) between the auditory cortex (Heschl’s gyrus [HG], planum temporale [PT]) and whole brain using seed correlation analysis in n = 21 BD euthymic patients and n = 20 matched healthy controls and associated it with verbal memory performance. In comparison to controls BD patients showed decreased functional connectivity between Heschl’s gyrus and planum temporale and the left superior and middle temporal gyrus. Additionally, fronto-temporal functional connectivity with the right inferior frontal/precentral gyrus and the insula was increased in patients. Verbal episodic memory deficits in the investigated sample of BD patients and language-related symptoms might therefore be associated with a diminished FC within the auditory/temporal gyrus and a compensatory fronto-temporal pathway.
BACKGROUND: In the heart, cytoplasmic actin networks are thought to have important roles in mechanical support, myofibrillogenesis, and ion channel function. However, subcellular localization of cytoplasmic actin isoforms and proteins involved in the modulation of the cytoplasmic actin networks are elusive. Mena and VASP are important regulators of actin dynamics. Due to the lethal phenotype of mice with combined deficiency in Mena and VASP, however, distinct cardiac roles of the proteins remain speculative. In the present study, we analyzed the physiological functions of Mena and VASP in the heart and also investigated the role of the proteins in the organization of cytoplasmic actin networks.
RESULTS: We generated a mouse model, which simultaneously lacks Mena and VASP in the heart. Mena/VASP double-deficiency induced dilated cardiomyopathy and conduction abnormalities. In wild-type mice, Mena and VASP specifically interacted with a distinct αII-Spectrin splice variant (SH3i), which is in cardiomyocytes exclusively localized at Z- and intercalated discs. At Z- and intercalated discs, Mena and β-actin localized to the edges of the sarcomeres, where the thin filaments are anchored. In Mena/VASP double-deficient mice, β-actin networks were disrupted and the integrity of Z- and intercalated discs was markedly impaired.
CONCLUSIONS: Together, our data suggest that Mena, VASP, and αII-Spectrin assemble cardiac multi-protein complexes, which regulate cytoplasmic actin networks. Conversely, Mena/VASP deficiency results in disrupted β-actin assembly, Z- and intercalated disc malformation, and induces dilated cardiomyopathy and conduction abnormalities.
Background: Simultaneous pancreas kidney transplantation (SPK), pancreas transplantation alone (PTA) or pancreas transplantation after kidney (PAK) are the only curative treatment options for patients with type 1 (juvenile) diabetes mellitus with or without impaired renal function. Unfortunately, transplant waiting lists for this indication are increasing because the current organ acceptability criteria are restrictive; morbidity and mortality significantly increase with time on the waitlist. Currently, only pancreas organs from donors younger than 50 years of age and with a body mass index (BMI) less than 30 are allocated for transplantation in the Eurotransplant (ET) area. To address this issue we designed a study to increase the available donor pool for these patients.
Methods/Design: This study is a prospective, multicenter (20 German centers), single blinded, non-randomized, two armed trial comparing outcome after SPK, PTA or PAK between organs with the currently allowed donor criteria versus selected organs from donors with extended criteria. Extended donor criteria are defined as organs procured from donors with a BMI of 30 to 34 or a donor age between 50 and 60 years. Immunosuppression is generally standardized using induction therapy with Myfortic, tacrolimus and low dose steroids. In principle, all patients on the waitlist for primary SPK, PTA or PAK are eligible for the clinical trial when they consent to possibly receiving an extended donor criteria organ. Patients receiving an organ meeting the current standard criteria for pancreas allocation (control arm) are compared to those receiving extended criteria organ (study arm); patients are blinded for a follow-up period of one year. The combined primary endpoint is survival of the pancreas allograft and pancreas allograft function after three months, as an early relevant outcome parameter for pancreas transplantation.
Discussion: The EXPAND Study has been initiated to investigate the hypothesis that locally allocated extended criteria organs can be transplanted with similar results compared to the currently allowed standard ET organ allocation. If our study shows a favorable comparison to standard organ allocation criteria, the morbidity and mortality for patients waiting for transplantation could be reduced in the future.
Trial registered at: NCT01384006
Surfactant proteins (SP) have been studied intensively in the respiratory system. Surfactant protein A and surfactant protein D are proteins belonging to the family of collectins each playing a major role in the innate immune system. The ability of surfactant protein A and surfactant protein D to bind various pathogens and facilitate their elimination has been described in a vast number of studies. Surfactant proteins are very important in modulating the host's inflammatory response and participate in the clearance of apoptotic cells. Surfactant protein B and surfactant protein C are proteins responsible for lowering the surface tension in the lungs. The aim of this study was an investigation of expression of surfactant proteins in the central nervous system to assess their specific distribution patterns. The second aim was to quantify surfactant proteins in cerebrospinal fluid of healthy subjects compared to patients suffering from different neuropathologies. The expression of mRNA for the surfactant proteins was analyzed with RT-PCR done with samples from different parts of the human brain. The production of the surfactant proteins in the brain was verified using immunohistochemistry and Western blot. The concentrations of the surfactant proteins in cerebrospinal fluid from healthy subjects and patients suffering from neuropathologic conditions were quantified using ELISA. Our results revealed that surfactant proteins are present in the central nervous system and that the concentrations of one or more surfactant proteins in healthy subjects differed significantly from those of patients affected by central autoimmune processes, CNS infections or cerebral infarction. Based on the localization of the surfactant proteins in the brain, their different levels in normal versus pathologic samples of cerebrospinal fluid and their well-known functions in the lungs, it appears that the surfactant proteins may play roles in host defense of the brain, facilitation of cerebrospinal fluid secretion and maintenance of the latter's rheological properties.
Background: The underlying axiom in applying generic drugs is the equivalence of their active ingredient with the (usually more expensive) innovator product, an all-embracing statement with the insidious result that physicians assume that the generic products have been subjected to the same rigorous testing regimens as the brand-name products. The present paper presents novel experimental data on an investigator-blinded comparison between the innovator imipenem antibiotic, and a number of its generics.
Methods: Particulate matter contamination of each group was visualized by means of a membrane filter method. Functional studies in an animal model–the dorsal skinfold chamber technique in mice-designed to simulate the state of microcirculatory dysfunction in intensive care patients was performed, in order to assess the influence of the particulate matter of each group on the functional capillary density of the striated skin muscle, after their intravenous injection.
Results: The results showed massive particulate contamination of the generics, in a size range relevant for impacting the microcirculation. The particulate contamination contributed in some generic groups to a significant shutdown of tissue perfusion.
Conclusion: The presented data underscore the need to raise the regulatory barriers for the entry of generics to the market, well beyond the simplistic proof of “bioequivalence”, which in no measure deals with the essential questions of quality and patient safety. If generics are used, they should be tested by a filter technique and optical microscopy, to ensure the absence especially of small particulate contaminants and their purity.
Sustained HIV suppression depends on a number of factors including therapy adherence, management of side effects, viral resistance and individual characteristics of patients and therapeutic settings. Treatment response rates range up to 90% in therapy naïve patients but decline to approximately 50% in patients who received several antiretrovirals during treatment history. Furthermore, HIV protease inhibitors (PI) and non nucleoside reverse transcriptase inhibitors (NNRTI) plasma concentrations display high inter- and intra individual variability and the therapeutic window is comparably narrow. In this therapeutic setting the personalization of dosing regimens has been suggested in many cases to tailor the ARV plasma concentrations with the intention to maximize therapy success and minimize side effects in the individual. However, personalizing therapy by modifying the dosing regimen bears the danger of losing therapeutic efficacy, increasing side effects or causing viral resistance.
This topical review identifies pharmacokinetic and pharmacodynamic models of antiretroviral therapy appraising the potential application to HIV therapy and discusses its future in the light of new drug classes and fix-dose combinations.
Transcription factors play a crucial role in regulating differentiation processes during human life and are important in disease. The basic helix-loop-helix transcription factors Tal1 and Lyl1 play a major role in the regulation of gene expression in the hematopoietic system and are involved in human leukemia. Tal2, which belongs to the same family of transcription factors as Tal1 and Lyl1, is also involved in human leukaemia. However, little is known regarding the expression and regulation of Tal2 in hematopoietic cells. Here we show that Tal2 is expressed in hematopoietic cells of the myeloid lineage. Interestingly, we found that usage of the Tal2 promoter is different in human and mouse cells. Two promoters, hP1 and hP2 drive Tal2 expression in human erythroleukemia K562 cells, however in mouse RAW cells only the mP1 promoter is used. Furthermore, we found that Tal2 expression is upregulated during oesteoclastogenesis. We show that Tal2 is a direct target gene of the myeloid transcription factor PU.1, which is a key transcription factor for osteoclast gene expression. Strikingly, PU.1 binding to the P1 promoter is conserved between mouse and human, but PU.1 binding to P2 was only detected in human K562 cells. Additionally, we provide evidence that Tal2 influences the expression of the osteoclastic differentiation gene TRACP. These findings provide novel insight into the expression control of Tal2 in hematopoietic cells and reveal a function of Tal2 as a regulator of gene expression during osteoclast differentiation.
Delayed wound repair in sepsis is associated with reduced local pro-inflammatory cytokine expression
(2013)
Sepsis is one of the main causes for morbidity and mortality in hospitalized patients. Moreover, sepsis associated complications involving impaired wound healing are common. Septic patients often require surgical interventions that in-turn may lead to further complications caused by impaired wound healing. We established a mouse model to the study delayed wound healing during sepsis distant to the septic focus point. For this reason cecal ligation and puncture (CLP) was combined with the creation of a superficial wound on the mouse ear. Control animals received the same procedure without CPL. Epithelialization was measured every second day by direct microscopic visualization up to complete closure of the wound. As interplay of TNF-α, TGF-β, matrix metalloproteinases (MMP), and tissue inhibitors of metalloproteinases (TIMP) is important in wound healing in general, TNF-α, TGF-β, MMP7, and TIMP1 were assessed immunohistochemical in samples of wounded ears harvested on days 2, 6, 10 and 16 after wounding. After induction of sepsis, animals showed a significant delay in wound epithelialization from day 2 to 12 compared to control animals. Complete wound healing was attained after mean 12.2± standard deviation (SD) 3.0 days in septic animals compared to 8.7± SD 1.7 days in the control group. Septic animals showed a significant reduction in local pro-inflammatory cytokine level of TNF-α on day 2 and day 6 as well as a reduced expression of TGF-β on day 2 in wounds. A significant lower expression of MMP7 as well as TIMP1 was also observed on day 2 after wounding. The induction of sepsis impairs wound healing distant to the septic focus point. We could demonstrate that expression of important cytokines for wound repair is deregulated after induction of sepsis. Thus restoring normal cytokine response locally in wounds could be a good strategy to enhance wound repair in sepsis.
The study objective was to assess the current status of HIV knowledge, attitudes and behavior (KAB) among employees of Namibian ministries. As most HIV campaigning takes place in the capital of Windhoek, an additional aim was to compare Windhoek to four regions (Hardap, Erongo, Oshana, and Caprivi). Between January and March 2011 a cross-sectional survey was conducted in two Namibian ministries, with participants selected randomly from the workforce. Data collection was based on questionnaires. 832 participants were included in the study (51.6% male). Nearly 90% of participants reported to have been tested for HIV before. Knowledge about HIV transmission ranged from 67% to 95% of correct answers, with few differences between the capital and regions. However, a knowledge gap regarding HIV transmission and prevention was seen. In particular, we found significantly lower knowledge regarding transmission from mother-to-child during pregnancy and higher rate of belief in a supernatural role in HIV transmission. In addition, despite many years of HIV prevention activities, a substantial proportion of employees had well-known HIV risk factors including multiple concurrent partnership rates (21%), intergenerational sex (19%), and lower testing rates for men (82% compared to women with 91%).
Background: Preeclampsia is one of the leading causes of maternal and perinatal mortality and morbidity worldwide and its pathogenesis is not totally understood. As a member of the chromosomal passenger complex and an inhibitor of apoptosis, survivin is a well-characterized oncoprotein. Its roles in trophoblastic cells remain to be defined.
Methods: The placental samples from 16 preeclampsia patients and 16 well-matched controls were included in this study. Real-time PCR, immunohistochemistry and Western blot analysis were carried out with placental tissues. Primary trophoblastic cells from term placentas were isolated for Western blot analysis. Cell proliferation, cell cycle analysis and immunofluorescence staining were performed in trophoblastic cell lines BeWo, JAR and HTR-8/SVneo.
Results: The survivin gene is reduced but the protein amount is hardly changed in preeclamptic placentas, compared to control placentas. Upon stress, survivin in trophoblastic cells is phosphorylated on its residue serine 20 by protein kinase A and becomes stabilized, accompanied by increased heat shock protein 90. Depletion of survivin induces chromosome misalignment, abnormal centrosome integrity, and reduced localization and activity of Aurora B at the centromeres/kinetochores in trophoblastic metaphase cells.
Conclusions: Our data indicate that survivin plays pivotal roles in cell survival and proliferation of trophoblastic cells. Further investigations are required to define the function of survivin in each cell type of the placenta in the context of proliferation, differentiation, apoptosis, angiogenesis, migration and invasion.
Background: MicroRNAs circulating in the blood, stabilized by complexation with proteins and/or additionally by encapsulation in lipid vesicles, are currently being evaluated as biomarkers. The consequences of their differential association with lipids/vesicles for their stability and use as biomarkers are largely unexplored and are subject of the present study.
Methods: The levels of a set of selected microRNAs were determined by quantitative reverse-transcription PCR after extraction from sera or vesicle- and non-vesicle fractions prepared from sera. The stability of these microRNAs after incubation with RNase A or RNase inhibitor, an inhibitor of RNase A family enzymes was studied.
Results: The levels of microRNA-1 and microRNA-122, but not those of microRNA-16, microRNA-21 and microRNA-142-3p, declined significantly during a 5-h incubation of the sera. RNase inhibitor prevented the loss of microRNAs in serum as well as the degradation of microRNA-122, a microRNA not expressed in blood cells, in whole blood. Stabilization of microRNA-122 was also achieved by hemolysis. Prolonged incubation of the sera led to enrichment of vesicle-associated relative to non-vesicle-associated microRNAs. Vesicle-associated microRNAs were more resistant to RNase A treatment than the respective microRNAs not associated with vesicles.
Conclusions: Serum microRNAs showed differential stability upon prolonged incubation. RNase inhibitor might be useful to robustly preserve the pattern of cell-free circulating microRNAs. In the case of microRNAs not expressed in blood cells this can also be achieved by hemolysis. Vesicle-associated microRNAs appeared to be more stable than those not associated with vesicles, which might be useful to disclose additional biomarker properties of miRNAs.
HIF1A reduces acute lung injury by optimizing carbohydrate metabolism in the alveolar epithelium
(2013)
Background: While acute lung injury (ALI) contributes significantly to critical illness, it resolves spontaneously in many instances. The majority of patients experiencing ALI require mechanical ventilation. Therefore, we hypothesized that mechanical ventilation and concomitant stretch-exposure of pulmonary epithelia could activate endogenous pathways important in lung protection.
Methods and Findings: To examine transcriptional responses during ALI, we exposed pulmonary epithelia to cyclic mechanical stretch conditions—an in vitro model resembling mechanical ventilation. A genome-wide screen revealed a transcriptional response similar to hypoxia signaling. Surprisingly, we found that stabilization of hypoxia-inducible factor 1A (HIF1A) during stretch conditions in vitro or during ventilator-induced ALI in vivo occurs under normoxic conditions. Extension of these findings identified a functional role for stretch-induced inhibition of succinate dehydrogenase (SDH) in mediating normoxic HIF1A stabilization, concomitant increases in glycolytic capacity, and improved tricarboxylic acid (TCA) cycle function. Pharmacologic studies with HIF activator or inhibitor treatment implicated HIF1A-stabilization in attenuating pulmonary edema and lung inflammation during ALI in vivo. Systematic deletion of HIF1A in the lungs, endothelia, myeloid cells, or pulmonary epithelia linked these findings to alveolar-epithelial HIF1A. In vivo analysis of 13C-glucose metabolites utilizing liquid-chromatography tandem mass-spectrometry demonstrated that increases in glycolytic capacity, improvement of mitochondrial respiration, and concomitant attenuation of lung inflammation during ALI were specific for alveolar-epithelial expressed HIF1A.
Conclusions: These studies reveal a surprising role for HIF1A in lung protection during ALI, where normoxic HIF1A stabilization and HIF-dependent control of alveolar-epithelial glucose metabolism function as an endogenous feedback loop to dampen lung inflammation.
Der ischämische Schlaganfall zählt zu den häufigsten Todesursachen in den Industrienationen und hinterlässt die meisten überlebenden Patienten in einer Pflegebedürftigkeit. Trotz der hohen Inzidenz und der gravierenden Folgen eines Schlaganfalls gibt es bislang keine ausreichende medikamentöse Therapie zum Schutz der Nervenzellen. Die akute Versorgung beschränkt sich auf die Lyse des Thrombus, welcher die betroffene Hirnarterie verschließt, und auf symptomatische Maßnahmen.
In der vorliegenden Dissertation wurden daher das neuroprotektiv wirkende Bilobalid, eine Substanz aus dem Ginkgo biloba Baum, und das anaplerotisch wirksame Triheptanoin auf ihre schützende Wirkung während eines ischämischen Schlaganfalls im Mausmodell untersucht. Zusätzlich wurden in der Bilobalid-Studie Tiere aus zwei verschiedenen Altersgruppen (6-8 Wochen gegen 18-24 Monate) verglichen. Der transiente Schlaganfall wurde in der Maus durch einstündigen Verschluss der mittleren Cerebralarterie (MCAO, middle cerebral artery occlusion) induziert.
Bilobalid wurde prophylaktisch eine Stunde vor Induktion des Schlaganfalls intraperitoneal (10 mg/kg) oder lokal in das betroffene Hirnareal (10 µM) verabreicht. Alle durchgeführten Experimente wiesen auf eine deutliche Neuroprotektion durch die Gabe von Bilobalid hin. Ein Tag nach MCAO war die Infarktfläche durch die Gabe von Bilobalid signifikant vermindert. In den durchgeführten motorischen Verhaltenstests schnitten die Bilobalid-behandelten Tiere wesentlich besser ab als unbehandelte Tiere. Der beobachtete Schutzeffekt von Bilobalid wurde auf mitochondriale Prozesse zurückgeführt: Die nach Ischämie beobachteten Defizite in Komplex I der mitochondrialen Atmungskette wurden durch die Gabe von Bilobalid deutlich vermindert. Bilobalid verringerte außerdem den enormen Anstieg von extrazellulärem Glutamat und das Ausmaß der mitochondrialen Schwellung während MCAO.
In der Altersstudie wurde deutlich, dass sowohl die motorische Aktivität der Tiere als auch einige zelluläre Prozesse wie die mitochondriale Atmung beeinträchtigt sind. Nichtsdestotrotz zeigte Bilobalid auch in gealterten Tieren einen deutlichen protektiven Effekt nach Ischämie.
Das anaplerotisch wirksame Triheptanoin wurde den Mäusen in einer 14-tätigen Fütterungsstudie verabreicht (33 % der Gesamt-Kalorien). Deutliche Schutzeffekte der Triheptanoin-Diät wurden nach Ischämie sowohl in TTC-gefärbten Hirnschnitten als auch in motorischen Verhaltenstests beobachtet. Durch den anaplerotischen Effekt sollte einerseits der Citratcyclus mit Acetyl-CoA und Succinyl-CoA gespeist werden, andererseits könnte Succinat in Komplex II der Atmungskette als direkter Energielieferant dienen. Dieser theoretische Ansatz wurde experimentell bestätigt: Die Fütterung mit Triheptanoin bewirkte eine signifikante Aktivitätssteigerung der mitochondrialen Komplexe II und IV nach MCAO. Die durch Ischämie gesenkten ATP-Spiegel und das Membranpotential wurden durch die anaplerotische Diät ebenfalls deutlich erhöht. Triheptanoin bewirkte zudem eine signifikante Reduktion des extrazellulären Glutamat-Anstiegs wŠhrend der MCAO.
Die Auswirkungen eines Schlaganfalls wurden demnach sowohl durch die prophylaktische Gabe von Bilobalid eine Stunde vor Ischämie als auch durch die 14-tägige Triheptanoin-Diät maßgeblich vermindert. Beide Substanzen zeigten im Mausmodell bemerkenswerte neuroprotektive Effekte und könnten daher auch beim Auftreten eines humanen Schlaganfalls entscheidende Vorteile bringen. Der präventive therapeutische Einsatz von Bilobalid oder Triheptanoin sollte daher in klinischen Studien weiter verfolgt werden.
Das Medizinstudium und die spätere Berufstätigkeit werden als stressig angesehen; dennoch liegen nur wenige Daten zur Stressbelastung von Medizinstudenten und Ärzten vor. Als Teil einer umfangreichen Erhebung zur Stressbelastung haben wir die Stressbelastung und Resilienz von Frankfurter Medizinstudenten in den ersten Wochen des 1. vorklinischen Semesters erhoben (Trierer Inventar zum chronischen Stress TICS, Resilienz-Skala RS11); an der Studie nahmen 348 von 383 Studienanfängern (90,8%) teil. Übereinstimmend mit Ergebnissen aus dem 5. Semester zeigen die Studenten des 1. Semesters hohe Werte insbesondere in den Teilskalen Überlastung und Überforderung; auffallend sind ebenfalls hohe Werte in den Skalen Soziale Isolation und Summenscore. Ein T-Score (altersnormierter Normalwert = 50) über der 2fachen Vertrauensgrenze findet sich im Summenscore (17,2%), chronische Besorgnis (17,8%), Überforderung (11,2%) und Überlastung (22,7%), während in anderen Skalen entsprechende Werte nur bei 1–5% der Teilnehmer erreicht wurden. Die Skalen Überlastung, Erfolgsdruck, chronische Besorgnis sowie der Summenscore sind weitgehend normalverteilt (Schiefe <0,2), dieser Wert beträgt für die anderen Skalen 0,45–0,65. Zwischen den Unterskalen finden sich Korrelationskoeffizienten >0,5 für Überlastung und Überforderung sowie chronischer Besorgnis, zwischen Überforderung und mangelnder sozialer Anerkennung, sozialer Isolierung und chronischer Besorgnis sowie zwischen sozialen Spannungen, sozialer Isolierung und chronischer Besorgnis. Parallel wurde die Resilienz mit Hilfe des Fragebogens RS11 erhoben (kein Optimum, hohe Werte weisen auf Resilienz hin). Bei einer Maximalpunktzahl von 77 erreichten die Studenten 62,2 +/– 8,8 Punkte, bei einer ausgeprägten rechtsschiefen Verteilung. Zwischen der Stressbelastung und der Resilienz fand sich keine relevante Korrelation, mit einem Maximalwert von –0,267 zwischen dem RS11-Score und der Subskala Überforderung. Die Daten belegen ein bereits zu Studienbeginn vorliegendes hohes Maß an Überlastung und Überforderung; dieser Stress korreliert nicht mit der Fähigkeit, mit Stress adäquat umzugehen (Resilienz).